var title_f1_51_1840="Pneumonia bulging fissure";
var content_f1_51_1840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pneumonia bulging fissure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 449px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CXR from a 55 year old female with bacteremic pneumococcal pneumonia. Shows a dense left lower lobe opacity with a bulging fissure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas J Marrie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1840=[""].join("\n");
var outline_f1_51_1840=null;
var title_f1_51_1841="Safety packing list";
var content_f1_51_1841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F85533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F85533&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Safety packing list",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 628px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * It is best not to use a card or phone that you shared with an abuser because he or she may be able to use them to find you.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Department of Health and Human Services Office on Women's Health. Violence Against Women: Safety planning for abusive situations. Available at:",
"     <a href=\"file://www.womenshealth.gov\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.womenshealth.gov",
"     </a>",
"     . (Accessed June 25, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1841=[""].join("\n");
var outline_f1_51_1841=null;
var title_f1_51_1842="Congential HSV 2";
var content_f1_51_1842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital herpes simplex viral disease-2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hepatic herpes simplex viral infection with infected cell in center.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1842=[""].join("\n");
var outline_f1_51_1842=null;
var title_f1_51_1843="Triangular fibrocartilage complex loading";
var content_f1_51_1843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Loading the triangular fibrocartilage complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A clinician can provoke&nbsp;signs of a triangular fibrocartilage complex injury by hyper-supinating the forearm and loading the wrist (ie, compressing the joint with an axial load) while it is held in a position of ulnar deviation and extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1843=[""].join("\n");
var outline_f1_51_1843=null;
var title_f1_51_1844="Dapsone (topical): Patient drug information";
var content_f1_51_1844=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dapsone (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/34/44579?source=see_link\">",
"     see \"Dapsone (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10883?source=see_link\">",
"     see \"Dapsone (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aczone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14965298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aczone&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dapsone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697586",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and hair from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use of other skin products may cause more irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699338",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze gel.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11648 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1844=[""].join("\n");
var outline_f1_51_1844=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016713\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14965298\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030930\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030929\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030934\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030935\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030937\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030932\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030933\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030938\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030939\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/7/29814?source=related_link\">",
"      Dapsone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/22/9573?source=related_link\">",
"      Dapsone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/20/39237?source=related_link\">",
"      Dapsone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/34/44579?source=related_link\">",
"      Dapsone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10883?source=related_link\">",
"      Dapsone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_51_1845="Acute rejection vascular II";
var content_f1_51_1845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vascular pattern of acute lung transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of acute vascular rejection demonstrating a perivascular lymphocytic infiltrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Kobzik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1845=[""].join("\n");
var outline_f1_51_1845=null;
var title_f1_51_1846="Liothyronine: Drug information";
var content_f1_51_1846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liothyronine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/27/44468?source=see_link\">",
"    see \"Liothyronine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/6/33894?source=see_link\">",
"    see \"Liothyronine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytomel&reg;;",
"     </li>",
"     <li>",
"      Triostat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cytomel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Thyroid Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypothyroidism:",
"     </b>",
"     Oral: 25 mcg/day increase by 12.5-25 mcg/day every 1-2 weeks to a maximum of 100 mcg/day; usual maintenance dose: 25-75 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients with cardiovascular disease: Refer to geriatric dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppression test",
"     </b>",
"     : (T",
"     <sub>",
"      3",
"     </sub>",
"     ): Oral: 75-100 mcg/day for 7 days; use lowest dose for elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myxedema:",
"     </b>",
"     Oral: Initial: 5 mcg/day; increase in increments of 5-10 mcg/day every 1-2 weeks. When 25 mcg/day is reached, dosage may be increased at intervals of 5-25 mcg/day every 1-2 weeks. Usual maintenance dose: 50-100 mcg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myxedema coma:",
"     </b>",
"     I.V.: 25-50 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients with known or suspected cardiovascular disease:",
"     </i>",
"     10-20 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Normally, at least 4 hours should be allowed between doses to adequately assess therapeutic response and no more than 12 hours should elapse between doses to avoid fluctuations in hormone levels. Oral therapy should be resumed as soon as the clinical situation has been stabilized and the patient is able to take oral medication. If levothyroxine rather than liothyronine sodium is used in initiating oral therapy, the prescriber should bear in mind that there is a delay of several days in the onset of levothyroxine activity and that I.V. therapy should be discontinued gradually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Simple (nontoxic) goiter:",
"     </b>",
"     Oral: Initial: 5 mcg/day; increase by 5-10 mcg every 1-2 weeks; after 25 mcg/day is reached, may increase dose by 12.5-25 mcg. Usual maintenance dose: 75 mcg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F189070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/6/33894?source=see_link\">",
"      see \"Liothyronine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Congenital hypothyroidism: Oral: 5 mcg/day increase by 5 mcg every 3-4 days until the desired response is achieved. Usual maintenance dose: 20 mcg/day for infants, 50 mcg/day for children 1-3 years of age, and adult dose for children &gt;3 years.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 5 mcg/day; increase by 5 mcg/day every 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16265632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16265633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mcg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triostat&reg;: 10 mcg/mL (1 mL) [contains ethanol 6.8%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mcg, 25 mcg, 50 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytomel&reg;: 5 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytomel&reg;: 25 mcg, 50 mcg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F189027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: For I.V. use only;",
"     <b>",
"      do not administer I.M. or SubQ",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Administer doses at least 4 hours, and no more than 12 hours, apart",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Resume oral therapy as soon as the clinical situation has been stabilized and the patient is able to take oral medication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     When switching to tablets, discontinue the injectable, initiate oral therapy at a low dosage and increase gradually according to response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     If",
"     <b>",
"      levothyroxine",
"     </b>",
"     is used for oral therapy, there is a delay of several days in the onset of activity; therefore, discontinue I.V. therapy gradually.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Replacement or supplemental therapy in hypothyroidism; management of nontoxic goiter; a diagnostic aid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Treatment of myxedema coma/precoma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7789503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of hemodynamically unstable potential organ donors increasing the quantity of organs available for transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Liothyronine may be confused with levothyroxine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       T3 is an error-prone abbreviation (mistaken as acetaminophen and codeine [ie, Tylenol&reg; #3])",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Cardiovascular: Arrhythmia (6%), tachycardia (3%), cardiopulmonary arrest (2%), hypotension (2%), MI (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic skin reactions, angina, CHF, fever, hypertension, phlebitis, twitching",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to liothyronine sodium or any component of the formulation; undocumented or uncorrected adrenal insufficiency; recent myocardial infarction or thyrotoxicosis; artificial rewarming (injection)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution and reduce dosage in patients with angina pectoris or other cardiovascular disease; chronic hypothyroidism predisposes patients to coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus and insipidus; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myxedema: Use with caution in patients with myxedema; symptoms may be exaggerated or aggravated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients; they may be more likely to have compromised cardiovascular function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Thyroid replacement requires periodic assessment of thyroid status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight reduction (unlabeled use):",
"     <b>",
"      [U.S. Boxed Warning]: Thyroid supplements are ineffective and potentially toxic for weight reduction.",
"     </b>",
"     <b>",
"      High doses may produce serious or even life-threatening toxic effects particularly when used with some anorectic drugs.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least 4 h prior to colesevelam, and at least 1 h before or 4-6 h after cholestyramine.  Specific recommendations for colestipol are not available. Monitor for decreased concentrations/effects of the thyroid product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral calcium polystyrene sulfonate and thyroid products (eg, levothyroxine) or administer calcium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Thyroid Products. Management: Administer oral thyroid products at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Thyroid Products may diminish the therapeutic effect of Sodium Iodide I131.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May decrease the serum concentration of Thyroid Products. Management: To minimize risk of interaction, separate dosing of oral sodium polystyrene sulfonate and thyroid products (e.g., levothyroxine) or administer sodium polystyrene sulfonate rectally. Monitor for signs/symptoms of hypothyroidism with concomitant use (oral).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Thyroid Products may increase the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Thyroid Products may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F189034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Endogenous thyroid hormones minimally cross the placenta; the fetal thyroid becomes active around the end of the first trimester. Liothyronine has not been found to increase the risk of teratogenic or adverse effects following maternal use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hypothyroidism may result in adverse neonatal and maternal outcomes. To prevent adverse events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Levothyroxine is considered the treatment of choice for the control of hypothyroidism during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F189057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12990097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous thyroid hormones are minimally found in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F189033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Liothyronine Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mcg/mL (1 mL): $462.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Triostat Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mcg/mL (1 mL): $481.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cytomel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mcg (100): $117.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (100): $154.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $235.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Liothyronine Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mcg (100): $80.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mcg (100): $105.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg (100): $160.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F189021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     T",
"     <sub>",
"      3",
"     </sub>",
"     , TSH, heart rate, blood pressure, renal function, clinical signs of hypo- and hyperthyroidism; TSH is the most reliable guide for evaluating adequacy of thyroid replacement dosage. TSH may be elevated during the first few months of thyroid replacement despite patients being clinically euthyroid. In cases where T",
"     <sub>",
"      4",
"     </sub>",
"     remains low and TSH is within normal limits, an evaluation of &ldquo;free&rdquo; (unbound) T",
"     <sub>",
"      4",
"     </sub>",
"     is needed to evaluate further increase in dosage.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F189024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Free T",
"     <sub>",
"      3",
"     </sub>",
"     , serum: 250-390 pg/dL; TSH: 0.4 and up to 10 (&ge;80 years) mIU/L; remains normal in pregnancy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cynomel (BF, BJ, CI, ET, FR, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MX, NE, NG, PE, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cytomel (BE, LU, NL);",
"     </li>",
"     <li>",
"      Cytomel 25 (IL);",
"     </li>",
"     <li>",
"      Dispon (IT);",
"     </li>",
"     <li>",
"      Halotri (ES);",
"     </li>",
"     <li>",
"      Iobolin (BR);",
"     </li>",
"     <li>",
"      Liothyronin (NO, PL, SE);",
"     </li>",
"     <li>",
"      Neo-Tiroimade (PT);",
"     </li>",
"     <li>",
"      T3 (GR);",
"     </li>",
"     <li>",
"      Tertroxin (AU, CZ, GB);",
"     </li>",
"     <li>",
"      Tetronine (KP);",
"     </li>",
"     <li>",
"      Thybon Henning (DE);",
"     </li>",
"     <li>",
"      Thyronine (JP);",
"     </li>",
"     <li>",
"      Thyrotardin inject. (DE);",
"     </li>",
"     <li>",
"      Ti-Tre (IT);",
"     </li>",
"     <li>",
"      Tri-Iodo-Tironina (AR);",
"     </li>",
"     <li>",
"      Trijodthyronin (AT, PL);",
"     </li>",
"     <li>",
"      Trijodthyronin BC (DE);",
"     </li>",
"     <li>",
"      Triyodotironina (ES);",
"     </li>",
"     <li>",
"      Triyotex (CR, DO, GT, HN, MX, PA, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exact mechanism of action is unknown; however, it is believed the thyroid hormone exerts its many metabolic effects through control of DNA transcription and protein synthesis; involved in normal metabolism, growth, and development; promotes gluconeogenesis, increases utilization and mobilization of glycogen stores, and stimulates protein synthesis, increases basal metabolic rate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak response: 2-3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed (95% in 4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2.5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dahlberg PA, Karlsson FA, and Wide L, &ldquo;Triiodothyronine Intoxication,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1979, 2(8144):700.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Helfand M and Crapo LM, &ldquo;Monitoring Therapy in Patients Taking Levothyroxine,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1990, 113(6):450-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/51/1846/abstract-text/2143640/pubmed\" id=\"2143640\" target=\"_blank\">",
"        2143640",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson DG and Campbell S, &ldquo;Hormonal and Metabolic Agents,&rdquo;",
"      <i>",
"       Geriatric Pharmacology",
"      </i>",
"      , Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosendale JD, Kauffman HM, McBride MA, et al, &ldquo;Aggressive Pharmacologic Donor Management Results in More Transplanted Organs,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2003, 75(4):482-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/51/1846/abstract-text/12605114/pubmed\" id=\"12605114\" target=\"_blank\">",
"        12605114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosengard BR, Feng S, Alfrey EJ, et al, &ldquo;Report of the Crystal City Meeting to Maximize the Use of Organs Recovered From the Cadaver Donor,&rdquo;",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2002, 2(8):701-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/51/1846/abstract-text/12243491/pubmed\" id=\"12243491\" target=\"_blank\">",
"        12243491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salim A, Martin M, Brown C, et al, &ldquo;Using Thyroid Hormone in Brain-Dead Donors to Maximize the Number of Organs Available for Transplantation,&rdquo;",
"      <i>",
"       Clin Transplant",
"      </i>",
"      , 2007, 21(3):405-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/51/1846/abstract-text/17488392 /pubmed\" id=\"17488392 \" target=\"_blank\">",
"        17488392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanders LR, &ldquo;Pituitary, Thyroid, Adrenal and Parathyroid Diseases in the Elderly,&rdquo;",
"      <i>",
"       Geriatric Medicine",
"      </i>",
"      , 1990, 475-87.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sawin CT, Geller A, Hershman JM, et al, &ldquo;The Aging Thyroid. The Use of Thyroid Hormone in Older Persons,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1989, 261(18):2653-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/51/1846/abstract-text/2709545/pubmed\" id=\"2709545\" target=\"_blank\">",
"        2709545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts NB, &ldquo;Use of a Sensitive Thyrotropin Assay for Monitoring Treatment With Levothyroxine,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1989, 149(2):309-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/51/1846/abstract-text/2644903/pubmed\" id=\"2644903\" target=\"_blank\">",
"        2644903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9563 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-504D3CBC15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1846=[""].join("\n");
var outline_f1_51_1846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709013\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189046\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189047\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189085\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189051\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189070\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189052\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265632\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265633\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189023\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189008\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189027\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189026\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7789503\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189090\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189083\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189030\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189012\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299607\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189017\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189019\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189034\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189057\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990097\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189033\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189021\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189024\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189035\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189011\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189029\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9563|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/27/44468?source=related_link\">",
"      Liothyronine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/6/33894?source=related_link\">",
"      Liothyronine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_51_1847="Keloids";
var content_f1_51_1847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Keloids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1847/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1847/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1847/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1847/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1847/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1847/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1847/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1847/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/51/1847/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term keloid is derived from Greek words meaning \"tumorlike.\" Keloids are benign fibrous growths present in scar tissue that form because of altered wound healing, with overproduction of extracellular matrix and dermal fibroblasts that have a high mitotic rate [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In some patients the resulting lesions are severely disfiguring and painful. Recurrence is common after treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise pathogenesis of keloid formation is unknown. For some reason, certain individuals, most commonly blacks, develop a hyperproliferation of fibroblasts in response to trauma or, less commonly, de novo. Any skin insult (eg, ear piercing, lacerations, secondarily infected skin lesions, surgery) can cause keloid formation in predisposed individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33178324\">",
"    <span class=\"h2\">",
"     Fibroblasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibroblast proliferation and collagen synthesis are markedly increased in keloidal scars [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Overexpression of growth factors, such as transforming growth factor-beta (TGF-beta), vascular endothelial growth factor (VEGF), and connective tissue growth factor (CTGF) appear to play a role in the formation of these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. TGF-beta is a regulator of fibroblast proliferation and collagen synthesis. In normal wound healing, transforming growth factor-beta (TGF-beta) activity diminishes upon the completion of wound repair, but in keloids TGF-beta is overproduced and poorly regulated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased numbers of platelet derived growth factor (PDGF) receptors on keloidal fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/10\">",
"     10",
"    </a>",
"    ] and overactivation of signals for insulin-like growth factor-I [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/11\">",
"     11",
"    </a>",
"    ] have also been implicated in the pathogenesis of keloids.",
"   </p>",
"   <p>",
"    Alteration of apoptosis (programmed cell death) has been implicated in the pathogenesis of keloids. In one study that compared the expression of 64 apoptosis-related genes in keloids and normal scars, underexpression of eight of these genes was found in the fibroblasts derived from keloid tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/12\">",
"     12",
"    </a>",
"    ]. The authors suggested that keloid fibroblasts fail to undergo physiologically programmed cell death, and therefore continue to produce connective tissue beyond the period expected for normal scars. Others have come to similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33178317\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Keloids occur more frequently in certain ethnic populations; people of African and Asian descent are most susceptible to the development of keloids [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/13\">",
"     13",
"    </a>",
"    ]. This observation and reports of familial cases suggest a genetic contribution to keloid development [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Studies of familial keloids have reported varied modes of inheritance, indicating that there may be multiple genetic disorders that influence keloid formation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/18\">",
"     18",
"    </a>",
"    ]. One study of 14 families suggested an autosomal dominant mode of inheritance with incomplete penetrance and variable expression [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple genes are likely to be involved in the development of keloids, and attempts to definitively identify the genes involved have been unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/18\">",
"     18",
"    </a>",
"    ]. A genome-wide association study identified four susceptibility loci on chromosomes 1q41, 3q22.3-23, and 15q21.3 in a Japanese population [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/19\">",
"     19",
"    </a>",
"    ]. However, no genes in these regions were definitively linked to keloid formation.",
"   </p>",
"   <p>",
"    Further studies are necessary to clarify the relationship between genetic background and keloid formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is based upon the clinical appearance of excessive scar tissue. Patients may be asymptomatic, but frequently have lesions that are pruritic, tender to palpation, or occasionally are the source of sharp, shooting pains. Most commonly keloids occur on the ears, neck, jaw, presternal chest, shoulders, and upper back (",
"    <a class=\"graphic graphic_picture graphicRef54044 graphicRef61382 \" href=\"UTD.htm?23/41/24217\">",
"     picture 1A-B",
"    </a>",
"    ). Acne keloidalis nuchae refers to inflamed pustules and papules on the posterior neck that often heal with keloid formation (",
"    <a class=\"graphic graphic_picture graphicRef58129 \" href=\"UTD.htm?24/17/24856\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hypertrophic scars may initially appear similar to keloids, but in contrast to the latter, hypertrophic scars do not extend beyond the margins of the wound (",
"    <a class=\"graphic graphic_picture graphicRef55411 \" href=\"UTD.htm?22/61/23505\">",
"     picture 3",
"    </a>",
"    ). While the treatment strategies are similar for both lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/20\">",
"     20",
"    </a>",
"    ], hypertrophic scars are far less likely to recur once treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best treatment is prevention in patients with a known predisposition. This includes preventing unnecessary trauma or surgery (including ear piercing, elective mole removal), whenever possible. Any skin problems in predisposed individuals (eg, acne, infections) should be treated as early as possible to minimize areas of inflammation. Patients who have acne keloidalis nuchae should avoid shaving in the neck region, and the posterior hair should only be trimmed with scissors and trimmed no shorter than one-eighth of an inch.",
"   </p>",
"   <p>",
"    A number of treatment options are available for painful or cosmetically disfiguring keloids:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intralesional corticosteroids",
"     </li>",
"     <li>",
"      Excision",
"     </li>",
"     <li>",
"      Silicone gel sheeting",
"     </li>",
"     <li>",
"      Cryosurgery",
"     </li>",
"     <li>",
"      Pressure earrings",
"     </li>",
"     <li>",
"      Radiation therapy",
"     </li>",
"     <li>",
"      Interferon alfa",
"     </li>",
"     <li>",
"      Intralesional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"     </li>",
"     <li>",
"      Intralesional",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"     </li>",
"     <li>",
"      Laser therapy",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combinations of these therapies are also effective [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Patients should be advised, however, that recurrences are possible despite therapy. The earlier keloids are treated, the more likely it is that they will respond to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     lntralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional corticosteroids are first-line therapy for most keloids. A systematic review found that up to 70 percent of patients respond to intralesional corticosteroid injection with flattening of keloids, although the recurrence rate is high in some studies (up to 50 percent at five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    , 5 to 40",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    can be injected as follows (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For local anesthesia, apply liquid nitrogen for 10 to 15 seconds or use EMLA cream under occlusion for 1.5 hours before injection. Permanent hypopigmentation may result if liquid nitrogen is used for 30 seconds or longer.",
"     </li>",
"     <li>",
"      Using a 27- or 30-gauge needle with the bevel directed up toward the skin, inject enough",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      to make the keloid blanch (usually 0.1 to 0.5 mL). Inject into the keloid as the needle is withdrawn from the skin. Be sure that the injection occurs in the bulk of the lesion and not underneath it, or lipoatrophy may occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A Luer-Lok (twist on) type of syringe should be used since injections are often made under pressure. Protective goggles are worn to avoid spraying medication or blood into the eyes.",
"   </p>",
"   <p>",
"    Injections can be repeated at monthly intervals, increasing the concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    by 10",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    on nonfacial lesions until the lesion softens and flattens, then decreasing the frequency and strength of injections. Do not exceed 40 mg of the drug per visit; atrophy and hypopigmentation may occur at higher doses. Surgical excision is recommended if there is no response after four injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scalpel excision may be indicated if injection therapy alone is unsuccessful or unlikely to result in significant improvement. Excision should be combined with preoperative, intraoperative, or postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    or interferon injections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/24\">",
"     24",
"    </a>",
"    ]. Recurrence rates from 45 to 100 percent have been reported in patients treated with excision alone; this falls to below 50 percent in patients treated with combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/22\">",
"     22",
"    </a>",
"    ]. Postoperative use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    every other day may reduce the rate of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/25\">",
"     25",
"    </a>",
"    ]. Referral to a dermatologist or plastic surgeon is indicated for excision because of the high rate of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Silicone gel sheeting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silicone gel sheeting has been used for the treatment of symptoms (eg, pain and itching) in patients with established keloids as well as for the management of evolving keloids and the prevention of keloids at the sites of new injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of controlled trials found some evidence that silicone gel sheeting may reduce the incidence of abnormal scarring, but concluded that any estimate of effect was uncertain because the underlying trials were of poor quality and highly susceptible to bias [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/30\">",
"     30",
"    </a>",
"    ]. Treatment with silicone gel sheeting appeared in some studies to improve elasticity of established abnormal scars, but the evidence was again of poor quality and susceptible to bias.",
"   </p>",
"   <p>",
"    The mechanism by which silicone gel sheeting might exert an anti-scarring effect is unknown, but may be related to hydration, generation of static electricity, or reduction of mast cells [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/26,27,31,32\">",
"     26,27,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Silicone gel sheeting and silicone gel are available by prescription and over-the-counter. The sheeting is clear and sticky and should be cut to fit the size of the keloid. The sheeting is placed on top of the keloid, taped into place, and left on for 12 to 24 hours per day. The sheet is washed daily and replaced every 10 to 14 days. Effectiveness is judged after two to six months of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cryosurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryosurgery is most useful in combination with other treatments for keloids [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], although up to 50 percent of patients may respond to cryotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/24,33\">",
"     24,33",
"    </a>",
"    ]. The major side effect is permanent hypopigmentation, limiting its use in patients with darker skin.",
"   </p>",
"   <p>",
"    A 10- to 30-second freeze-thaw cycle is used and can be repeated up to three times per treatment session. Therapy is repeated once per month until response occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pressure earrings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uncontrolled studies have reported that pressure therapy is an effective treatment for keloids of the ear following piercing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/34\">",
"     34",
"    </a>",
"    ]. The earrings, also called Zimmer splints, are splints that are inexpensive and molded to the appropriate size, cosmetically altered to appear as earrings. One online source for these is Delasco (www.delasco.com).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/24,35-37\">",
"     24,35-37",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/38\">",
"     38",
"    </a>",
"    ], have found radiation therapy to be highly effective in reducing keloid recurrence, with improvement rates of 70 to 90 percent when administered after surgical excision. A small randomized trial of treatments after surgery found recurrences in 2 of 16 earlobe keloids (13 percent) treated with radiation therapy and in 4 of 12 earlobe keloids (33 percent) treated with steroid injections [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, concern regarding the potential long-term risks (eg, malignancy) associated with using radiation for an essentially benign disorder limits its utility in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/40\">",
"     40",
"    </a>",
"    ]. Only a few cases of malignancy that may have been associated with radiation therapy for keloids have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/37,40\">",
"     37,40",
"    </a>",
"    ]. Although causation cannot be confirmed in these cases, caution should still be used when prescribing radiation therapy for keloids, particularly when treating younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/37\">",
"     37",
"    </a>",
"    ]. Radiation therapy may occasionally be appropriate as treatment for keloids that are resistant to other therapies. In addition, radiation therapy may be indicated for lesions that are not amenable to resection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Keloid characteristics may play a role in predicting the response to therapy. A study in which patients were treated with Sr-90 brachytherapy after surgical excision of keloids found that the location (thorax), size (large), and etiology (result of a burn injury) are factors that may predict a less favorable response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa injections may reduce recurrence rates postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/43\">",
"     43",
"    </a>",
"    ]. However, all currently available studies of interferon therapy suffer from methodologic problems, making an evidence-based recommendation regarding its use difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intralesional fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU) may be of benefit for keloids. In a case series, 28 patients were treated with intralesional 5-FU 50",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    with a volume of 0.5 to 2.0 mL per session for up to 12 weekly sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/44\">",
"     44",
"    </a>",
"    ]. Greater than 50 percent response to treatment reportedly occurred in the majority of patients after 12 weeks. Ulceration occurred in 21 percent of patients.",
"   </p>",
"   <p>",
"    In a second case series of 20 patients, 17 patients had at least 50 percent improvement and only one showed no improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/45\">",
"     45",
"    </a>",
"    ]. Among the 19 patients with any improvement, nine patients had a recurrence within one year.",
"   </p>",
"   <p>",
"    Intralesional 5-FU can be used in combination with intralesional corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulsed dye laser",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsed dye laser treatment can be beneficial for keloids [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], and appears to induce keloid regression through suppression of keloid fibroblast proliferation, and induction of apoptosis and enzyme activity.",
"   </p>",
"   <p>",
"    Combination treatment with pulsed dye laser plus intralesional therapy with corticosteroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    may be superior to either approach alone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies that have been used for keloids include intralesional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    cream. There is currently insufficient evidence to make definitive recommendations about these therapies when used alone; as discussed above, imiquimod may provide benefit when used after surgical excision. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Excision'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF WOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is very limited evidence on how best to manage minor wounds to minimize scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/30,49,50\">",
"     30,49,50",
"    </a>",
"    ]. Reduction of scarring is frequently desired independent of concerns about keloid formation.",
"   </p>",
"   <p>",
"    Based mainly on clinical experience, we suggest keeping wounds moist and covered during the early healing phase. This appears to hasten wound healing, which could potentially decrease scar formation. We apply a lubricant followed by a dressing. Plain petrolatum is an appropriate lubricant for uninfected wounds. We avoid aloe, since plant extracts can be sensitizing and cause an allergic contact dermatitis. A nonadherent dressing such as Telfa can be held in place by occlusion with tape, DuoDerm, or silicon gel pads.",
"   </p>",
"   <p>",
"    Topical application of vitamin E may cause a contact dermatitis and does not appear to improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1847/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Hyperpigmentation after wound healing is common, particularly with sun exposure. We suggest covering a scar with tape or an adhesive dressing (eg, Band-Aid&reg;) when out in the sun for three months after wound healing (although this may be impractical for some scars and can sometimes cause contact dermatitis), and also applying a broad spectrum sunscreen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=see_link\">",
"     \"Selection of sunscreen and sun-protective measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For wounds that are in locations more worrisome for hypertrophic scars (eg, over joints or under high stress), we sometimes use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    in the acute wound phase, although this can be irritating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/39/9842?source=see_link\">",
"       \"Patient information: Keloids (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33178348\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keloids are benign, fibroproliferative lesions that represent abnormal wound repair. The pathogenesis of keloids is unknown, but may involve abnormalities in fibroblast proliferation, collagen synthesis, or fibroblast apoptosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased occurrence of keloids in certain ethnic populations and the identification of families demonstrating keloid inheritance suggest that genes influence susceptibility to keloid formation. However, specific genes responsible for keloid formation have not been identified. (See",
"      <a class=\"local\" href=\"#H33178317\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Keloids present as firm nodules that may be pruritic, tender, or painful. In contrast to hypertrophic scars, keloids extend beyond the margin of the wound. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of treatments are available for the management of keloids. Intralesional corticosteroids are the first-line therapy for most lesions, and the majority of patients will improve with this therapy. Potential consequences of intralesional corticosteroids include cutaneous atrophy and hypopigmentation. If surgical excision is performed to treat a keloid, adjuvant therapy is necessary to decrease the risk of recurrence. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/1\">",
"      Nemeth AJ. Keloids and hypertrophic scars. J Dermatol Surg Oncol 1993; 19:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/2\">",
"      Teofoli P, Barduagni S, Ribuffo M, et al. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J Dermatol Sci 1999; 22:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/3\">",
"      Nakaoka H, Miyauchi S, Miki Y. Proliferating activity of dermal fibroblasts in keloids and hypertrophic scars. Acta Derm Venereol 1995; 75:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/4\">",
"      Fujiwara M, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration. Br J Dermatol 2005; 153:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/5\">",
"      Uitto J, Perejda AJ, Abergel RP, et al. Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts. Proc Natl Acad Sci U S A 1985; 82:5935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/6\">",
"      Marneros AG, Krieg T. Keloids--clinical diagnosis, pathogenesis, and treatment options. J Dtsch Dermatol Ges 2004; 2:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/7\">",
"      Lee TY, Chin GS, Kim WJ, et al. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg 1999; 43:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/8\">",
"      Colwell AS, Phan TT, Kong W, et al. Hypertrophic scar fibroblasts have increased connective tissue growth factor expression after transforming growth factor-beta stimulation. Plast Reconstr Surg 2005; 116:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/9\">",
"      Wolfram D, Tzankov A, P&uuml;lzl P, Piza-Katzer H. Hypertrophic scars and keloids--a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 2009; 35:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/10\">",
"      Haisa M, Okochi H, Grotendorst GR. Elevated levels of PDGF alpha receptors in keloid fibroblasts contribute to an enhanced response to PDGF. J Invest Dermatol 1994; 103:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/11\">",
"      Ohtsuru A, Yoshimoto H, Ishihara H, et al. Insulin-like growth factor-I (IGF-I)/IGF-I receptor axis and increased invasion activity of fibroblasts in keloid. Endocr J 2000; 47 Suppl:S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/12\">",
"      Sayah DN, Soo C, Shaw WW, et al. Downregulation of apoptosis-related genes in keloid tissues. J Surg Res 1999; 87:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/13\">",
"      Chike-Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg 2009; 23:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/14\">",
"      Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol 2001; 137:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/15\">",
"      BLOOM D. Heredity of keloids; review of the literature and report of a family with multiple keloids in five generations. N Y State J Med 1956; 56:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/16\">",
"      Chen Y, Gao JH, Liu XJ, et al. Characteristics of occurrence for Han Chinese familial keloids. Burns 2006; 32:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/17\">",
"      Clark JA, Turner ML, Howard L, et al. Description of familial keloids in five pedigrees: evidence for autosomal dominant inheritance and phenotypic heterogeneity. BMC Dermatol 2009; 9:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/18\">",
"      Shih B, Bayat A. Genetics of keloid scarring. Arch Dermatol Res 2010; 302:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/19\">",
"      Nakashima M, Chung S, Takahashi A, et al. A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet 2010; 42:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/20\">",
"      Zurada JM, Kriegel D, Davis IC. Topical treatments for hypertrophic scars. J Am Acad Dermatol 2006; 55:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/21\">",
"      English RS, Shenefelt PD. Keloids and hypertrophic scars. Dermatol Surg 1999; 25:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/22\">",
"      Berman B, Bieley HC. Adjunct therapies to surgical management of keloids. Dermatol Surg 1996; 22:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/23\">",
"      Hirshowitz B, Lerner D, Moscona AR. Treatment of keloid scars by combined cryosurgery and intralesional corticosteroids. Aesthetic Plast Surg 1982; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/24\">",
"      Shaffer JJ, Taylor SC, Cook-Bolden F. Keloidal scars: a review with a critical look at therapeutic options. J Am Acad Dermatol 2002; 46:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/25\">",
"      Tyring S. Imiquimod applied topically: A novel immune response modifier. Skin Therapy Lett 2001; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/26\">",
"      Berman B, Flores F. Comparison of a silicone gel-filled cushion and silicon gel sheeting for the treatment of hypertrophic or keloid scars. Dermatol Surg 1999; 25:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/27\">",
"      Hirshowitz B, Lindenbaum E, Har-Shai Y, et al. Static-electric field induction by a silicone cushion for the treatment of hypertrophic and keloid scars. Plast Reconstr Surg 1998; 101:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/28\">",
"      Gold MH. Topical silicone gel sheeting in the treatment of hypertrophic scars and keloids. A dermatologic experience. J Dermatol Surg Oncol 1993; 19:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/29\">",
"      Fulton JE Jr. Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars. Dermatol Surg 1995; 21:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/30\">",
"      O'Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2006; :CD003826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/31\">",
"      Chang CC, Kuo YF, Chiu HC, et al. Hydration, not silicone, modulates the effects of keratinocytes on fibroblasts. J Surg Res 1995; 59:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/32\">",
"      Eishi K, Bae SJ, Ogawa F, et al. Silicone gel sheets relieve pain and pruritus with clinical improvement of keloid: possible target of mast cells. J Dermatolog Treat 2003; 14:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/33\">",
"      Zouboulis CC, Blume U, B&uuml;ttner P, Orfanos CE. Outcomes of cryosurgery in keloids and hypertrophic scars. A prospective consecutive trial of case series. Arch Dermatol 1993; 129:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/34\">",
"      Russell R, Horlock N, Gault D. Zimmer splintage: a simple effective treatment for keloids following ear-piercing. Br J Plast Surg 2001; 54:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/35\">",
"      Wagner W, Alfrink M, Micke O, et al. Results of prophylactic irradiation in patients with resected keloids--a retrospective analysis. Acta Oncol 2000; 39:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/36\">",
"      Klumpar DI, Murray JC, Anscher M. Keloids treated with excision followed by radiation therapy. J Am Acad Dermatol 1994; 31:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/37\">",
"      Ragoowansi R, Cornes PG, Moss AL, Glees JP. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. Plast Reconstr Surg 2003; 111:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/38\">",
"      van de Kar AL, Kreulen M, van Zuijlen PP, Oldenburger F. The results of surgical excision and adjuvant irradiation for therapy-resistant keloids: a prospective clinical outcome study. Plast Reconstr Surg 2007; 119:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/39\">",
"      Sclafani AP, Gordon L, Chadha M, Romo T 3rd. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. Dermatol Surg 1996; 22:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/40\">",
"      Botwood N, Lewanski C, Lowdell C. The risks of treating keloids with radiotherapy. Br J Radiol 1999; 72:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/41\">",
"      Malaker K, Vijayraghavan K, Hodson I, Al Yafi T. Retrospective analysis of treatment of unresectable keloids with primary radiation over 25 years. Clin Oncol (R Coll Radiol) 2004; 16:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/42\">",
"      Viani GA, Stefano EJ, Afonso SL, De Fendi LI. Postoperative strontium-90 brachytherapy in the prevention of keloids: results and prognostic factors. Int J Radiat Oncol Biol Phys 2009; 73:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/43\">",
"      Conejo-Mir JS, Corbi R, Linares M. Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids. J Am Acad Dermatol 1998; 39:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/44\">",
"      Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg 2004; 30:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/45\">",
"      Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, et al. Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. J Am Acad Dermatol 2005; 52:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/46\">",
"      Alster TS. Laser treatment of hypertrophic scars, keloids, and striae. Dermatol Clin 1997; 15:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/47\">",
"      Alster TS, Williams CM. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 1995; 345:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/48\">",
"      Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg 2006; 32:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/49\">",
"      Atkinson JA, McKenna KT, Barnett AG, et al. A randomized, controlled trial to determine the efficacy of paper tape in preventing hypertrophic scar formation in surgical incisions that traverse Langer's skin tension lines. Plast Reconstr Surg 2005; 116:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/50\">",
"      Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast Surg 2008; 32:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/51\">",
"      Baumann LS, Spencer J. The effects of topical vitamin E on the cosmetic appearance of scars. Dermatol Surg 1999; 25:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1847/abstract/52\">",
"      Khoosal D, Goldman RD. Vitamin E for treating children's scars. Does it help reduce scarring? Can Fam Physician 2006; 52:855.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5569 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1847=[""].join("\n");
var outline_f1_51_1847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33178348\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33178324\">",
"      Fibroblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33178317\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      lntralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Silicone gel sheeting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cryosurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pressure earrings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intralesional fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulsed dye laser",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT OF WOUNDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33178348\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5569\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5569|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/53/33623\" title=\"picture 1A\">",
"      Keloid ear lobe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/24/25984\" title=\"picture 1B\">",
"      Keloids from acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/17/24856\" title=\"picture 2\">",
"      Acne keloidalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/61/23505\" title=\"picture 3\">",
"      Hypertrophic scar",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/39/9842?source=related_link\">",
"      Patient information: Keloids (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33447?source=related_link\">",
"      Selection of sunscreen and sun-protective measures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_51_1848="Scaphoid fractures";
var content_f1_51_1848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Scaphoid fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1848/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1848/contributors\">",
"     Kevin deWeber, MD, FAAFP, FACSM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1848/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1848/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1848/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1848/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/51/1848/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scaphoid fractures are among the most common injuries. They frequently occur following a fall onto an outstretched hand. X-rays taken soon after the injury may not reveal a fracture, but the clinician should assume one is present until definitive proof otherwise is obtained.",
"   </p>",
"   <p>",
"    This topic will review the diagnosis and nonoperative management of scaphoid (navicular) fractures in adults. An overview of carpal fractures and a discussion of how to evaluate thumb pain in adults are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9928?source=see_link\">",
"     \"Evaluation of the patient with thumb pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3513896\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal fractures account for 18 percent of hand fractures and 6 percent of all fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Fractures to bones of the proximal carpal row (ie, scaphoid, lunate, triquetrum, and pisiform) are more frequent than fractures of the distal row (ie, trapezium, trapezoid, capitate, and hamate). Of all carpal fractures, scaphoid fractures are by far the most common, accounting for 10 percent of all hand fractures and 60 to 70 percent of all carpal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of scaphoid fractures in the military showed an unadjusted incidence of",
"    <span class=\"nowrap\">",
"     1.21/1000",
"    </span>",
"    person-years. In addition, males and whites had a higher relative risk, and 20 to 24 year olds had the highest incidence at",
"    <span class=\"nowrap\">",
"     1.64/1000",
"    </span>",
"    person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/4\">",
"     4",
"    </a>",
"    ]. According to data from the United States National Electronic Injury Surveillance System, the estimated incidence in the population at large is 1.47",
"    <span class=\"nowrap\">",
"     fractures/100,000",
"    </span>",
"    person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scaphoid is the largest bone of the proximal carpal row and is located on the radial aspect of the hand just distal to the radius itself (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"UTD.htm?37/16/38146\">",
"     image 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78359 \" href=\"UTD.htm?26/34/27172\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56302 \" href=\"UTD.htm?41/25/42386\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69097 \" href=\"UTD.htm?1/31/1527\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51990 \" href=\"UTD.htm?4/46/4838\">",
"     figure 4",
"    </a>",
"    ). In lateral profile, the scaphoid is shaped like an hourglass. The scaphoid articulates with the trapezium, trapezoid, capitate, and lunate. The radioscaphoid and scapholunate ligaments anchor the scaphoid proximally. The radial collateral ligament attaches to its lateral surface.",
"   </p>",
"   <p>",
"    The palmar carpal branch of the radial artery supplies the scaphoid via the bone&rsquo;s distal pole and then proceeds to the proximal pole. Thus, blood supply to the distal pole is tenuous and can be interrupted by a fracture, thereby increasing the risk of nonunion (",
"    <a class=\"graphic graphic_figure graphicRef50525 \" href=\"UTD.htm?38/10/39075\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Nonunion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most common classification of scaphoid fractures categorizes them by location: distal third (distal pole), central third (waist), and proximal third (proximal pole). Approximately 65 percent of scaphoid fractures occur at the waist, 15 percent at the proximal pole, 10 percent at the distal body, and 8 percent at the tuberosity (a protuberance at the distal palmar aspect) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the scaphoid can occur either with direct axial compression or with hyperextension of the wrist, such as with a fall onto an outstretched hand. When the wrist is loaded in this manner and is dorsiflexed greater than 95 degrees, the indentation (waist) in the midbody of the scaphoid is forced against the dorsal lip of the distal radius, creating a mechanism for injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/1,7\">",
"     1,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, the patient with a scaphoid fracture reports sustaining an injury involving an axial load on the wrist or a fall onto an outstretched hand. Pain is localized to the radial aspect of the wrist, often in the area just proximal to the thumb metacarpal. Swelling may or may not be noticeable, but if present, is usually on the dorsoradial aspect of the wrist.",
"   </p>",
"   <p>",
"    Range of motion may be only slightly reduced unless there is a concomitant fracture dislocation. Grip strength is typically reduced.",
"   </p>",
"   <p>",
"    Focal tenderness is usually present in one of three places:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The volar prominence at the distal wrist crease for distal pole fractures.",
"     </li>",
"     <li>",
"      The anatomic snuff box (see below) for waist fractures, which are most common.",
"     </li>",
"     <li>",
"      Just distal to Lister's Tubercle (a longitudinal bony prominence of the distal radius located just to the ulnar side of the extensor carpi radialis tendon) for proximal pole fractures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pertinent anatomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The anatomic snuffbox is located proximal to the base of the thumb between the extensor pollicis longus tendon medially and extensor pollicis brevis and abductor pollicis longus tendons laterally (",
"    <a class=\"graphic graphic_picture graphicRef82858 \" href=\"UTD.htm?41/27/42419\">",
"     picture 1",
"    </a>",
"    ). A good method for evaluating the body of the scaphoid is to gently bring the patient&rsquo;s wrist into ulnar deviation and slight volar flexion, and then, palpate the anatomic snuffbox (",
"    <a class=\"graphic graphic_picture graphicRef82859 \" href=\"UTD.htm?35/44/36547\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Scaphoid fractures are often occult and a high index of suspicion should be maintained for any patient with wrist pain following trauma. Any tenderness in the snuffbox should be treated as a scaphoid fracture until proven otherwise [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3514524\">",
"     'Immobilization (casting) and general management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In one prospective observational study of 41 patients with tenderness at the anatomic snuffbox following a fall onto an outstretched hand and no evidence of fracture on plain radiographs, the most accurate examination tests for detecting the presence of an occult fracture of the scaphoid or adjacent bones was the reproduction of pain when the patient pinched the tips of their thumb and index finger together or pronated their forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/8\">",
"     8",
"    </a>",
"    ]. MRI was used as the gold standard for determining the presence of an occult fracture. Of the 10 examination techniques tested, none showed a sensitivity greater than 79 percent (forearm pronation) or a specificity greater than 75 percent (pinch test).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PLAIN RADIOGRAPHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For suspected scaphoid fractures, standard radiographs include posteroanterior (PA), true lateral, and scaphoid views of the wrist (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 graphicRef78664 graphicRef58484 \" href=\"UTD.htm?22/19/22840\">",
"     image 1A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83486 \" href=\"UTD.htm?23/58/24483\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83488 \" href=\"UTD.htm?29/19/30004\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83487 \" href=\"UTD.htm?2/8/2180\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75655 \" href=\"UTD.htm?12/45/13010\">",
"     image 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74559 \" href=\"UTD.htm?14/59/15295\">",
"     image 6",
"    </a>",
"    ). The scaphoid view is a PA picture taken with the wrist in full pronation and ulnar deviation. This view shows the scaphoid in its longitudinal axis without superimposed shadows from the distal radius. &nbsp;",
"   </p>",
"   <p>",
"    Plain radiographs, particularly those taken at the time of injury, are limited in their capacity to detect scaphoid fractures. Extensive clinical experience and observational studies support this notion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Oblique fractures of the middle portion of the scaphoid body may be particularly difficult to detect on plain radiographs and if missed, can lead to poor outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, observational studies suggest that plain radiographs do not reliably show fracture detail, such as displacement. As an example, a study in which two hand surgeons, two musculoskeletal radiologists, and two senior orthopedic residents assessed plain x-rays of scaphoid fractures created in cadavers reported a sensitivity of 78 percent for identifying fracture displacement of 1 mm at the scaphoid waist and an accuracy of 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/12\">",
"     12",
"    </a>",
"    ]. A blinded observational study of 30 scaphoid fractures in which six experienced clinicians were asked to determine whether displacement was present reported a sensitivity of 75 percent and an accuracy of 68 percent for plain x-rays [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If fracture alignment is unclear on plain radiographs, an MRI or CT scan, with images taken along the long axis, can be obtained to correctly identify the degree of displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Knowledge of normal carpal anatomy is essential for determining the presence of a fracture or dislocation, especially when interpreting the lateral view. In lateral radiographs, the distal radius, lunate, and capitate should align along a longitudinal axis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78664 \" href=\"UTD.htm?9/13/9424\">",
"     image 1B",
"    </a>",
"    ). In addition, the scapholunate angle should fall between 40 and 60 degrees. This angle is formed by a line bisecting the scaphoid in its longitudinal axis and another line bisecting the lunate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76002 \" href=\"UTD.htm?1/44/1728\">",
"     image 7",
"    </a>",
"    ). Larger or smaller angles indicate ligamentous instability or a fracture.",
"   </p>",
"   <p>",
"    Plain radiographs should be evaluated for signs of ligament disruption, specifically of the scapholunate ligament. These signs include a widened space (&gt;3 mm) between the scaphoid and the lunate (the \"Terry Thomas\" sign). Widening can be accentuated by taking a PA x-ray with the hand closed in a fist and the wrist in ulnar deviation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52517 \" href=\"UTD.htm?14/30/14816\">",
"     image 8",
"    </a>",
"    ). Undetected scapholunate ligament injuries can lead to disruption of the proximal carpal row and a condition known as scapholunate advanced collapse or SLAC wrist (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75552 \" href=\"UTD.htm?28/26/29088\">",
"     image 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of the adult with acute wrist pain\", section on 'Scapholunate dissociation, lunate dislocation, and related injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SUSPECTED FRACTURE WITH NEGATIVE PLAIN RADIOGRAPHS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3514601\">",
"    <span class=\"h2\">",
"     Approach to imaging and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a fracture is compressed or minimally displaced, plain radiographs taken at the time of injury may be unrevealing. Therefore, the management of symptomatic patients with negative x-rays often consists of immobilization in a short-arm thumb spica cast for 7 to 10 days followed by reimaging with plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. This approach is sound, but may result in approximately 75 to 90 percent of patients being immobilized for a week or more, with only a soft tissue injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Although this traditional approach is useful in many patients, faster methods of detection can be used when rapid diagnosis is necessary. &nbsp;",
"   </p>",
"   <p>",
"    Approaches that allow more rapid and definitive diagnosis and avoid prolonged immobilization in those with soft tissue injury include repeat imaging at three to five days using a radionuclide bone scan (ie, bone scintigraphy) or immediate imaging at presentation using computed tomography (CT) or magnetic resonance imaging (MRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient cannot tolerate prolonged immobilization (eg, athlete or worker who cannot tolerate a prolonged absence) and cost is not a major concern, obtaining a CT or MRI study may be the best approach. CT is more readily available and relatively less costly, but MRI provides additional information about soft tissue injuries that may be present.",
"   </p>",
"   <p>",
"    According to a systematic review of studies assessing methods for detecting scaphoid fractures, the imaging modalities most often used had the following test characteristics, based upon data pooled from the relevant included studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone scintigraphy: sensitivity 97.8 percent (95% CI 95.6-99.3); specificity 93.5 percent (95% CI 91.3-95.3)",
"     </li>",
"     <li>",
"      MRI: sensitivity 97.7 percent (95% CI 94.8-99.5); specificity 99.8 percent (95% CI 99.3-100)",
"     </li>",
"     <li>",
"      CT: sensitivity 85.2 percent (95% CI 73.5-94); specificity 99.5 percent (95% CI 98.4-99.9)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preferred approach depends upon a number of factors including the need for a speedy diagnosis, cost, resource availability, and local expertise. Financial assessment should consider not only the cost of the imaging study used, but also the costs entailed in lost work days and repeat office visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3514608\">",
"    <span class=\"h2\">",
"     Radionuclide bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of a scaphoid fracture, a bone scan (ie, bone scintigraphy) shows focal increased uptake after 72 hours. In addition, according to several reviews, a negative bone scan virtually excludes a scaphoid fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/9,19-21\">",
"     9,19-21",
"    </a>",
"    ]. However, although sensitive, bone scan is less specific for a scaphoid fracture than MRI or CT and may be positive due to other injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/6,18\">",
"     6,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors of one systematic review of bone scintigraphy for suspected scaphoid fracture provide a diagnostic algorithm in which a bone scan is performed after three to seven days has elapsed since the initial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/19\">",
"     19",
"    </a>",
"    ]. According to multiple observational studies, scanning in this time frame detects all fractures and minimizes costs from additional follow-up (radiographs, office visit charges, and further diagnostic testing) and time lost from work. However, bone scintigraphy may result in unnecessary immobilization due to false positive results, and its cost is not inconsequential.",
"   </p>",
"   <p>",
"    A bone scan can detect other bony injuries in cases of suspected scaphoid fracture. One prospective study reported 20 non-scaphoid wrist fractures in a sample of 50 patients with clinical signs and symptoms of a scaphoid fracture, but negative initial plain x-rays [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3514460\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) can be used to diagnose scaphoid fractures and delineate details of the fracture pattern. As noted in the systematic review described above, CT is highly specific for detecting scaphoid fractures but less sensitive than MRI or bone scan [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3514601\">",
"     'Approach to imaging and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3514424\">",
"    <span class=\"h2\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is highly sensitive and specific for diagnosing scaphoid fractures when standard radiographs are inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3514601\">",
"     'Approach to imaging and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When a fracture is present, the MRI shows diminished signal in T1-weighted images and increased signal in T2-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/22\">",
"     22",
"    </a>",
"    ]. Findings interpreted as \"edema\" can occur with fractures, microtrabecular fractures (bone bruise), or ligamentous injuries.",
"   </p>",
"   <p>",
"    According to one research group, a protocol for evaluating suspected carpal fractures using MRI would be roughly equivalent in cost to the traditional approach of immobilization followed by repeat plain radiographs and would provide an earlier definitive diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3514453\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another modality for early diagnosis of scaphoid fracture is high spatial-resolution sonography [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/16,23\">",
"     16,23",
"    </a>",
"    ]. Sonography is not as well studied as alternative imaging methods.",
"   </p>",
"   <p>",
"    In a series of 54 cases of wrist injury, cortical disruption identified sonographically was found to have a sensitivity for scaphoid fracture (determined by follow-up plain x-ray, CT, or MRI) of 100 percent, specificity of 98 percent, and diagnostic accuracy of 98 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/16\">",
"     16",
"    </a>",
"    ]. Using sonographic evidence of hematoma or hemarthrosis as a criterion, sensitivity was unchanged, but specificity and accuracy were decreased (65 percent, and 68 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open fractures and those associated with neurovascular compromise require emergent surgical referral.",
"   </p>",
"   <p>",
"    Scaphoid fractures that are displaced by &gt;1 mm or are associated with an increased tilt of the lunate (typically dorsal) should be referred to an orthopedic or hand surgeon. Lunate tilt may increase the scapholunate angle. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Plain radiographs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other reasons for referral include: associated carpal instability, evidence of nonunion during follow-up, osteonecrosis, and possible scapholunate dissociation. If the patient is unwilling or unable to wear a cast for up to three months, consider referral for operative fixation.",
"   </p>",
"   <p>",
"    Multiple randomized trials have found no significant differences in long-term function or radiologic healing between patients treated surgically or conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. More rapid return to work or sport can be expected with open reduction and internal fixation (ORIF) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/3,27,28\">",
"     3,27,28",
"    </a>",
"    ]. As an example, in one uncontrolled series involving 12 athletes, all returned to activity at five to eight weeks following treatment with ORIF [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/27\">",
"     27",
"    </a>",
"    ]. For any patient treated operatively, the clinician should determine the timing for return to sports or work in consultation with the surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8912143\">",
"    <span class=\"h1\">",
"     DELAYED PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, patients present for care several days or weeks following trauma, believing that the initial injury was only a wrist or thumb sprain. Good results are often obtained in such cases, but the risk of nonunion is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/11,29,30\">",
"     11,29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series, 29 of 30 patients presenting with a scaphoid fracture between two weeks to five months following their injury went on to form osseous unions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/11\">",
"     11",
"    </a>",
"    ]. However, according to another series of 285 scaphoid fractures, nonunion rates can reach 40 percent when diagnosis and treatment are delayed by four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, proper evaluation and close follow-up are crucial. Nevertheless, a review of 88 scaphoid fracture nonunions noted that initial x-rays were not obtained in 14 percent of patients who sought immediate medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Nonunion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NONUNION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arterial flow to the scaphoid enters via the distal pole and travels to the proximal pole. This blood supply is tenuous, increasing the risk of nonunion, particularly with fractures at the waist and proximal end. Nonunion may occur in as many as 5 to 10 percent of all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/10\">",
"     10",
"    </a>",
"    ]. In one series of 160 scaphoid nonunions, risk factors associated with nonunion included proximal fractures, fracture instability, and delay in care [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/10,31\">",
"     10,31",
"    </a>",
"    ]. Evidence of nonunion necessitates referral to an orthopedic surgeon. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for surgical referral'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2\">",
"     'Pertinent anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3514524\">",
"    <span class=\"h1\">",
"     IMMOBILIZATION (CASTING) AND GENERAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a definitive diagnosis cannot be determined at presentation and a scaphoid fracture is suspected on clinical grounds, even if radiographs are negative, the patient should be placed in a thumb spica splint or preferably, a thumb spica cast until a definitive imaging study can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/2,3,20,32\">",
"     2,3,20,32",
"    </a>",
"    ]. If there is concern about swelling, the cast can be bivalved (ie, cut longitudinally on opposite sides) and wrapped with an elastic bandage.",
"   </p>",
"   <p>",
"    The following figures describe how to make a thumb spica cast (",
"    <a class=\"graphic graphic_picture graphicRef74904 graphicRef60347 graphicRef69030 graphicRef80982 graphicRef59780 graphicRef70527 graphicRef50574 graphicRef61312 graphicRef74550 \" href=\"UTD.htm?43/11/44218\">",
"     picture 3A-I",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For most patients, pain is adequately managed with over-the-counter analgesics. Concerns about the effects of nonsteroidal anti-inflammatory medications on fracture healing are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H23#H23\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Possible effect on fracture healing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ice may be applied acutely to reduce swelling and pain, but if a splint is applied, the patient should be warned not to get it wet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1510267\">",
"    <span class=\"h2\">",
"     Summary of casting recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal scaphoid fractures and possible occult fractures are best immobilized in a short-arm thumb spica cast with the wrist in slight extension. A midbody or proximal non-displaced scaphoid fracture that is to be managed nonoperatively should be placed in a long-arm cast that includes thumb immobilization, during the early weeks of healing.",
"   </p>",
"   <p>",
"    A systematic review of randomized trials (n = 5) investigating nonoperative treatment of acute scaphoid fractures (number of patients 523) reported that nonunion rates and functional outcome did not differ according to cast type (eg, short-arm versus long-arm; wrist extension versus flexion) but emphasized the limited methodological quality of the eligible studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Non-displaced distal scaphoid fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a non-displaced (&lt;1 mm) distal fracture is noted, definitive treatment consists of immobilization in a short-arm thumb spica cast with the thumb IP joint free [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/2,3,20,32\">",
"     2,3,20,32",
"    </a>",
"    ]. That thumb interphalangeal (IP) joint movement does not impair healing was best illustrated in a prospective trial that randomly assigned 392 patients with an acute non-displaced scaphoid fracture to either a thumb spica cast (IP joint immobilized) or a standard short-arm cast (IP joint not immobilized) and reported on the results of 292 fractures followed for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/34\">",
"     34",
"    </a>",
"    ]. The incidence of nonunion was independent of the type of cast used. Casting the wrist in slight flexion and radial deviation has been recommended by some, but no randomized trials have been performed to assess this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/3,32\">",
"     3,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Non-displaced midbody or proximal fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-displaced midbody or proximal scaphoid fractures are initially treated for six weeks with immobilization in a long-arm thumb spica cast with the thumb interphalangeal joint free. After six weeks, this can be converted to a short-arm cast until complete healing is evident. Transition to a short-arm cast limits elbow stiffness. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Follow-up care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This approach is supported by a prospective study of 51 patients with non-displaced midbody or proximal scaphoid fractures that reported more rapid healing in those treated with a long-arm thumb spica cast initially, compared to those placed in a short-arm thumb spica cast for the entire period of immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-displaced fractures are followed serially with radiographs every two weeks. Guidelines for the duration of immobilization of scaphoid fractures are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distal pole &ndash; 4 to 6 weeks",
"     </li>",
"     <li>",
"      Waist (midbody) &ndash; 10 to 12 weeks",
"     </li>",
"     <li>",
"      Proximal pole &ndash; 12 to 20 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, immobilization should be continued until fracture union is documented on radiographs. CT can be used if healing is not well visualized on plain films.",
"   </p>",
"   <p>",
"    Ninety to 95 percent union rates have been achieved with appropriate cast immobilization of non-displaced fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. Exercises to maintain finger, elbow, and shoulder range of motion should be performed while the wrist is immobilized.",
"   </p>",
"   <p>",
"    If at three to four months radiographic healing is not evident, referral to a hand surgeon should be obtained for possible treatment with a bone stimulator or surgical correction with bone grafting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with non-displaced fractures treated with a short-arm thumb spica cast can be allowed to return to full activity, including non-contact sports, if the cast does not interfere with activity or sport-specific functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1848/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. The clinician should carefully monitor the integrity of the cast and ensure proper immobilization. After the cast is removed, the wrist should continue to be protected for two months with rigid splinting, while the patient participates in non-contact sports or other strenuous activity.",
"   </p>",
"   <p>",
"    Physical or occupational therapy is strongly encouraged because of the weakness and decreased range of motion that typically results from prolonged casting. As mentioned above, during activity the wrist should continue to be protected for at least two months, until strength is at least 80 percent of the uninjured side and the range of motion has returned to near-normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=see_link\">",
"       \"Patient information: Common wrist injuries (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scaphoid fractures are the most common carpal bone fracture and typically occur from a fall onto an outstretched arm with the wrist in dorsiflexion. Suspect a scaphoid fracture in any patient with wrist pain following a fall. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs taken soon after an injury may not reveal evidence of a fracture. Management of such cases consists of advanced imaging if an immediate diagnosis is needed or immobilization and repeat imaging with a bone scan (after three to five days) or plain x-rays (after 7 to 10 days). Check x-rays carefully for concomitant injury of the scapholunate ligament. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Plain radiographs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Management of suspected fracture with negative plain radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The scaphoid has a tenuous blood supply that runs from distal to proximal leading to the possibility of nonunion or osteonecrosis with fractures of the proximal pole. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Nonunion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All fractures that are displaced (&gt;1 mm) and those with a significantly increased or decreased scapholunate angle should be immobilized in a thumb spica splint and referred for orthopedic evaluation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indications for surgical referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-displaced fractures (&le;1 mm) of the distal scaphoid can be treated in a short-arm thumb spica cast, typically for 6 to 10 weeks. Non-displaced fractures at the waist or proximal third of the scaphoid can be treated in a long-arm thumb spica cast for six weeks, followed by a short-arm cast until healing is documented. These fractures require a longer period of immobilization. If prolonged immobilization cannot be tolerated, refer the patient for operative fixation. (See",
"      <a class=\"local\" href=\"#H3514524\">",
"       'Immobilization (casting) and general management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Athletes and workers engaged in heavy labor must continue to wear protection (rigid splint) for two months after radiographic healing is noted. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Return to sport or work'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H813139\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dobyns JH, Beckerbaugh RD, Bryan RS, et al. Fractures of the hand and wrist. In: Hand Surgery, 3rd, Flynn JE (Ed), Williams &amp; Wilkins, Philadelphia 1982.",
"    </li>",
"    <li>",
"     Eiff MP, Hatch RL, Calbach WL. Carpal fractures. In: Fracture Management for Primary Care, 2nd, Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/3\">",
"      Geissler WB. Carpal fractures in athletes. Clin Sports Med 2001; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/4\">",
"      Wolf JM, Dawson L, Mountcastle SB, Owens BD. The incidence of scaphoid fracture in a military population. Injury 2009; 40:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/5\">",
"      Van Tassel DC, Owens BD, Wolf JM. Incidence estimates and demographics of scaphoid fracture in the U.S. population. J Hand Surg Am 2010; 35:1242.",
"     </a>",
"    </li>",
"    <li>",
"     Seitz WH Jr, Papandrea RF. Fractures and dislocations of the wrist. In: Rockwood and Green's Fractures in Adults, 5th, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     Geissler W, Slade JF. Fractures of the carpal bones. In: Operative Hand Surgery, 6th, Green DP (Ed), Churchill Livingstone, Philadelphia 2011. p.639.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/8\">",
"      Unay K, Gokcen B, Ozkan K, et al. Examination tests predictive of bone injury in patients with clinically suspected occult scaphoid fracture. Injury 2009; 40:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/9\">",
"      Phillips TG, Reibach AM, Slomiany WP. Diagnosis and management of scaphoid fractures. Am Fam Physician 2004; 70:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/10\">",
"      Adams JE, Steinmann SP. Acute scaphoid fractures. Orthop Clin North Am 2007; 38:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/11\">",
"      Chen AC, Lee MS, Ueng SW, Chen WJ. Management of late-diagnosed scaphoid fractures. Injury 2010; 41:e10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/12\">",
"      Bernard SA, Murray PM, Heckman MG. Validity of conventional radiography in determining scaphoid waist fracture displacement. J Orthop Trauma 2010; 24:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/13\">",
"      Lozano-Calder&oacute;n S, Blazar P, Zurakowski D, et al. Diagnosis of scaphoid fracture displacement with radiography and computed tomography. J Bone Joint Surg Am 2006; 88:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/14\">",
"      Bhat M, McCarthy M, Davis TR, et al. MRI and plain radiography in the assessment of displaced fractures of the waist of the carpal scaphoid. J Bone Joint Surg Br 2004; 86:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/15\">",
"      Dorsay TA, Major NM, Helms CA. Cost-effectiveness of immediate MR imaging versus traditional follow-up for revealing radiographically occult scaphoid fractures. AJR Am J Roentgenol 2001; 177:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/16\">",
"      Hauger O, Bonnefoy O, Moinard M, et al. Occult fractures of the waist of the scaphoid: early diagnosis by high-spatial-resolution sonography. AJR Am J Roentgenol 2002; 178:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/17\">",
"      Yin ZG, Zhang JB, Kan SL, Wang XG. Diagnosing suspected scaphoid fractures: a systematic review and meta-analysis. Clin Orthop Relat Res 2010; 468:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/18\">",
"      Yin ZG, Zhang JB, Kan SL, Wang XG. Diagnostic accuracy of imaging modalities for suspected scaphoid fractures: meta-analysis combined with latent class analysis. J Bone Joint Surg Br 2012; 94:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/19\">",
"      Chakravarty D, Sloan J, Brenchley J. Risk reduction through skeletal scintigraphy as a screening tool in suspected scaphoid fracture: a literature review. Emerg Med J 2002; 19:507.",
"     </a>",
"    </li>",
"    <li>",
"     McCue FC III, Bruce JF Jr, Koman JD. Wrist and hand. In: DeLee and Drez's Orthopedic Sports Medicine Principles, 2nd, Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/21\">",
"      Beeres FJ, Hogervorst M, Rhemrev SJ, et al. A prospective comparison for suspected scaphoid fractures: bone scintigraphy versus clinical outcome. Injury 2007; 38:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/22\">",
"      Smith M, Bain GI, Turner PC, Watts AC. Review of imaging of scaphoid fractures. ANZ J Surg 2010; 80:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/23\">",
"      Herneth AM, Siegmeth A, Bader TR, et al. Scaphoid fractures: evaluation with high-spatial-resolution US initial results. Radiology 2001; 220:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/24\">",
"      Saed&eacute;n B, T&ouml;rnkvist H, Ponzer S, H&ouml;glund M. Fracture of the carpal scaphoid. A prospective, randomised 12-year follow-up comparing operative and conservative treatment. J Bone Joint Surg Br 2001; 83:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/25\">",
"      Dias JJ, Dhukaram V, Abhinav A, et al. Clinical and radiological outcome of cast immobilisation versus surgical treatment of acute scaphoid fractures at a mean follow-up of 93 months. J Bone Joint Surg Br 2008; 90:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/26\">",
"      Vinnars B, Pietreanu M, Bodestedt A, et al. Nonoperative compared with operative treatment of acute scaphoid fractures. A randomized clinical trial. J Bone Joint Surg Am 2008; 90:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/27\">",
"      Rettig AC, Kollias SC. Internal fixation of acute stable scaphoid fractures in the athlete. Am J Sports Med 1996; 24:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/28\">",
"      Muramatsu K, Doi K, Kuwata N, et al. Scaphoid fracture in the young athlete--therapeutic outcome of internal fixation using the Herbert screw. Arch Orthop Trauma Surg 2002; 122:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/29\">",
"      Langhoff O, Andersen JL. Consequences of late immobilization of scaphoid fractures. J Hand Surg Br 1988; 13:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/30\">",
"      Wong K, von Schroeder HP. Delays and poor management of scaphoid fractures: factors contributing to nonunion. J Hand Surg Am 2011; 36:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/31\">",
"      Inoue G, Shionoya K, Kuwahata Y. Herbert screw fixation for scaphoid nonunions. An analysis of factors influencing outcome. Clin Orthop Relat Res 1997; :99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/32\">",
"      Rettig ME, Dassa GL, Raskin KB, Melone CP Jr. Wrist fractures in the athlete. Distal radius and carpal fractures. Clin Sports Med 1998; 17:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/33\">",
"      Doornberg JN, Buijze GA, Ham SJ, et al. Nonoperative treatment for acute scaphoid fractures: a systematic review and meta-analysis of randomized controlled trials. J Trauma 2011; 71:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/34\">",
"      Clay NR, Dias JJ, Costigan PS, et al. Need the thumb be immobilised in scaphoid fractures? A randomised prospective trial. J Bone Joint Surg Br 1991; 73:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1848/abstract/35\">",
"      Gellman H, Caputo RJ, Carter V, et al. Comparison of short and long thumb-spica casts for non-displaced fractures of the carpal scaphoid. J Bone Joint Surg Am 1989; 71:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 197 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1848=[""].join("\n");
var outline_f1_51_1848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3513896\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PLAIN RADIOGRAPHS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT OF SUSPECTED FRACTURE WITH NEGATIVE PLAIN RADIOGRAPHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3514601\">",
"      Approach to imaging and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3514608\">",
"      Radionuclide bone scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3514460\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3514424\">",
"      MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3514453\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8912143\">",
"      DELAYED PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NONUNION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3514524\">",
"      IMMOBILIZATION (CASTING) AND GENERAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1510267\">",
"      Summary of casting recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Non-displaced distal scaphoid fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Non-displaced midbody or proximal fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H813139\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/197\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/197|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/16/38146\" title=\"diagnostic image 1A\">",
"      Normal adult wrist AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/13/9424\" title=\"diagnostic image 1B\">",
"      Normal adult wrist lateral radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/17/24863\" title=\"diagnostic image 1C\">",
"      Normal adult scaphoid radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/58/24483\" title=\"diagnostic image 2\">",
"      X-ray scaphoid fracture AP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/19/30004\" title=\"diagnostic image 3\">",
"      X-ray scaphoid fracture lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/8/2180\" title=\"diagnostic image 4\">",
"      X-ray scaphoid fracture oblique view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/45/13010\" title=\"diagnostic image 5\">",
"      Scaphoid fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/59/15295\" title=\"diagnostic image 6\">",
"      Scaphoid fx dislocation xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/44/1728\" title=\"diagnostic image 7\">",
"      Measuring scapholunate angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/30/14816\" title=\"diagnostic image 8\">",
"      Scapholunate dissociation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/26/29088\" title=\"diagnostic image 9\">",
"      Scapholunate advanced collapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/197|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/34/27172\" title=\"figure 1\">",
"      Anatomy wrist dorsal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42386\" title=\"figure 2\">",
"      Anatomy wrist radial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/31/1527\" title=\"figure 3\">",
"      Anatomy of the volar aspect of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4838\" title=\"figure 4\">",
"      Wrist hand bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/10/39075\" title=\"figure 5\">",
"      Scaphoid arterial supply",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/197|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/27/42419\" title=\"picture 1\">",
"      Wrist anatomic snuffbox location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/44/36547\" title=\"picture 2\">",
"      Palpation of scaphoid in anatomic snuffbox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/15/4336\" title=\"picture 3A\">",
"      Thumb spica cast 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/58/6048\" title=\"picture 3B\">",
"      Thumb spica cast 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/59/38832\" title=\"picture 3C\">",
"      Thumb spica cast 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/1/23569\" title=\"picture 3D\">",
"      Thumb spica cast 4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/60/28608\" title=\"picture 3E\">",
"      Thumb spica cast 5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/54/35681\" title=\"picture 3F\">",
"      Thumb spica cast 6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/52/28483\" title=\"picture 3G\">",
"      Thumb spica cast 7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/7/44146\" title=\"picture 3H\">",
"      Thumb spica cast 8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/32/17920\" title=\"picture 3I\">",
"      Thumb spica cast 9",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12632?source=related_link\">",
"      Evaluation of the adult with acute wrist pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9928?source=related_link\">",
"      Evaluation of the patient with thumb pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/20/7491?source=related_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_51_1849="Modes of cardiac pacing: Nomenclature and selection";
var content_f1_51_1849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Modes of cardiac pacing: Nomenclature and selection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1849/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1849/contributors\">",
"     David L Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1849/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1849/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1849/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/51/1849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been established that bradycardia or a conduction disorder warrants permanent pacing, the most appropriate pacing mode for the patient must be selected. The choice depends upon the specific abnormality that is present, since a wide range of pacemaker functions have been developed to accommodate specific clinical needs (",
"    <a class=\"graphic graphic_table graphicRef51504 \" href=\"UTD.htm?13/36/13900\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To facilitate the use and understanding of pacemakers, a standardized classification code has been developed. Most patients can be managed with one of two or three common modes (AAI, VVI, or DDD), with or without rate-responsiveness.",
"   </p>",
"   <p>",
"    The majority of contemporary pacemakers are versatile and capable of the most commonly used pacing modes and basic functions (ie, mode-switching and rate-responsiveness). Some features, such as rate-drop pacing and managed ventricular pacing, are available in selected devices.",
"   </p>",
"   <p>",
"    Pacemaker nomenclature and the clinical application of common pacing modes and functions will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Five position code",
"    </span>",
"    &nbsp;&mdash;&nbsp;A three-letter code describing the basic function of the various pacing systems was first proposed in 1974 by a combined task force from the American Heart Association and the American College of Cardiology. Since that time, responsibility for periodically updating the code has been assumed by a committee from the North American Society of Pacing and Electrophysiology (NASPE) and the British Pacing and Electrophysiology Group (BPEG). The code, which has five positions, is designated the NBG code for pacing nomenclature (",
"    <a class=\"graphic graphic_table graphicRef68327 \" href=\"UTD.htm?1/46/1772\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The code is generic and does not describe specific or unique functional characteristics for each device. When a code includes only three or four characters, it can be assumed that the positions not mentioned are \"O\" or absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Position I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first position reflects the chamber(s) paced. \"A\" indicates the atrium, \"V\" indicates the ventricle, and \"D\" means dual chamber (ie, both the atrium and the ventricle).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Position II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second position refers to the chamber(s) sensed. The letters are the same as those for the first position: \"A\" for atrium, \"V\" for ventricle, \"D\" for dual. An additional option \"O\" indicates an absence of sensing. Programmed in this mode, a device will pace automatically at a specified rate, ignoring any intrinsic rhythm. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Asynchronous pacing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Manufacturers sometimes use \"S\" in the first and second positions to indicate that the device is capable of pacing only a single cardiac chamber. Once the device is implanted and connected to a lead in either the atrium or the ventricle, \"S\" should be changed to \"A\" or \"V\" in the clinical record to reflect the chamber in which pacing and sensing are occurring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Position III",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third position refers to how the pacemaker responds to a sensed event.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"I\" indicates that a sensed event inhibits the output pulse and causes the pacemaker to recycle for one or more timing cycles.",
"     </li>",
"     <li>",
"      \"T\" indicates that an output pulse is triggered in response to a sensed event.",
"     </li>",
"     <li>",
"      \"D\" indicates that there are dual modes of response. This designation is restricted to dual chamber systems. An event sensed in the atrium inhibits the atrial output but triggers a ventricular output. There is a programmable delay between the sensed atrial event and the triggered ventricular output to mimic the normal PR interval. If the ventricular lead senses a native ventricular signal during the programmed delay, it will inhibit the ventricular output.",
"     </li>",
"     <li>",
"      \"O\" indicates no response to sensed input; it is most commonly used in conjunction with an \"O\" in the second position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Position IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fourth position reflects rate modulation, also referred to as rate responsive or rate adaptive pacing. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Rate responsiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"R\" in the fourth position indicates that the pacemaker has rate modulation and incorporates a sensor to adjust its programmed paced heart rate in response to patient activity. From a practical standpoint, \"R\" is the only indicator commonly used in the fourth position.",
"     </li>",
"     <li>",
"      \"O\" indicates that rate modulation is either unavailable or disabled. \"O\" is often omitted from the fourth position (ie, DDD is the same as DDDO).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Position V",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rarely used fifth position specifies only the location or absence of multisite pacing, defined as stimulation sites in both atria, both ventricles, more than one stimulation site in any single chamber, or a combination of these.",
"   </p>",
"   <p>",
"    The fifth position of the code is rarely used.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"O\" means no multisite pacing",
"     </li>",
"     <li>",
"      \"A\" indicates multisite pacing in the atrium or atria",
"     </li>",
"     <li>",
"      \"V\" indicates multisite pacing in the ventricle or ventricles",
"     </li>",
"     <li>",
"      \"D\" indicates dual multisite pacing in both atrium and ventricle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common application of multisite pacing is biventricular pacing for the management of heart failure. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above basic pacing modes, modern pacemakers have additional features to improve performance in a variety of specific clinical settings. Mode switching and rate responsiveness are available in the majority of pacemakers. Some features such as rate drop response and managed ventricular pacing are available in select devices and can be utilized as specific clinical situations demand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mode switching",
"    </span>",
"    &nbsp;&mdash;&nbsp;In dual chamber pacing systems",
"    <span class=\"nowrap\">",
"     (DDD/DDDR",
"    </span>",
"    or less commonly,",
"    <span class=\"nowrap\">",
"     VDD/VDDR),",
"    </span>",
"    the ventricle will be paced following every sensed atrial event, up to a programmed maximum ventricular rate. If the patient develops a paroxysmal atrial tachyarrhythmia (eg, atrial fibrillation), the ventricle would then be paced at this maximum programmed rate for the duration of the arrhythmia, which is obviously undesirable.",
"   </p>",
"   <p>",
"    Mode switching refers to automatic reprogramming of a pacemaker to a mode that no longer tracks the intrinsic atrial rate, usually VVI, DDI, or DVI with or without rate responsiveness. When the sensed atrial rate again falls below the mode switching cutoff and the device assumes that a physiologic rhythm has been restored (ie, with termination of the arrhythmia), the pacing mode automatically reverts to the original programming.",
"   </p>",
"   <p>",
"    One report evaluated 48 patients with a history of paroxysmal atrial tachyarrhythmias and complete heart block who had a mode switching pacemaker; the patients preferred this pacing mode to conventional DDDR or VVIR pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/2\">",
"     2",
"    </a>",
"    ]. Inappropriate mode switching and tracking of atrial tachyarrhythmias were uncommon.",
"   </p>",
"   <p>",
"    Most contemporary pacemakers have mode switching capabilities. This feature can be activated or disabled, depending upon the clinical situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Rate responsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, rate responsiveness, also referred to as rate modulation or rate adaptation, refers to the ability of a pacemaker to adjust its programmed paced rate based upon patient activity. A variety of sensors have been designed to determine when a patient is physically active (eg, vibration, minute ventilation, change in right ventricular impedance). The range of heart rates, the pace of acceleration and deceleration, and the degree of activity required to initiate this response are all programmable in rate-adaptive pacing modes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rate drop",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rate drop is designed to minimize symptoms of neurocardiogenic syncope. If a patient's heart rate drops at a rapid rate or falls below a specific level (both adjustable parameters), a response is triggered in which the pacemaker will pace the heart at an accelerated rate (eg, 100",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    for a defined period of time (eg, two minutes).",
"   </p>",
"   <p>",
"    Since neurocardiogenic syncope often has both bradycardic and vasodepressor components, the intention is to treat both problems with a transient increase in heart rate in an effort to raise the cardiac output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Modes to minimize ventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right ventricular (RV) pacing causes the right ventricle to contract before the left ventricle, and causes the septum to contract before the lateral wall of the LV, simulating the effects of left bundle branch block. This phenomenon is referred to as ventricular dyssynchrony or asynchrony. Whether due to RV pacing or intrinsic conduction abnormalities, dyssynchrony can cause or exacerbate heart failure in some patients and increase the frequency of atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=see_link\">",
"     \"Overview of cardiac pacing in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5367?source=see_link\">",
"     \"The role of pacemakers in the prevention of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many patients who receive a pacemaker or implantable cardiac defibrillator (ICD), native AV conduction is hemodynamically preferable to RV pacing. With an increased understanding of the detrimental effects of RV pacing, efforts have been made to develop pacing modes that minimize ventricular pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Examples of novel pacing strategies for this purpose include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular avoidance pacing algorithms &mdash; A dual chamber device can be programmed to pace AAI (allowing native conduction), but if loss of AV conduction is sensed, the pacemaker will switch to DDD pacing for some period of time until the algorithm once again looks for intrinsic AV conduction. In different studies, this approach was associated with a markedly lower rate of frequency of ventricular pacing compared to conventional dual chamber pacing (9 versus 99 percent and 4 versus 74 percent in two studies) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AV search hysteresis &mdash; A dual chamber device can be programmed DDD with a preset AV delay, but at a programmed interval (eg, every 32 to 1024 beats) will allow that preset AV delay to prolong by up to 100 percent to see if native conduction occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/6\">",
"       6",
"      </a>",
"      ]. If conduction with a long PR occurs, the programmed AV delay is automatically increased to the extent necessary to allow native conduction (usually up to another predetermined limit, such as a doubling of the originally programmed interval).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Biventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, dyssynchrony is unavoidable due to intrinsic conduction disease or inevitable ventricular pacing. If such a patient also has heart failure and left ventricular dysfunction, synchrony may be restored with biventricular pacing, or cardiac resynchronization therapy (CRT), which improves outcomes in selected patients. Cardiac resynchronization therapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PACING MODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selecting the ideal pacing mode, the patient's overall physical condition, associated medical problems, exercise capacity, and chronotropic response to exercise must be considered along with the underlying rhythm disturbance. Some of the various ventricular and atrial pacing systems available and their NBG codes are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef79459 \" href=\"UTD.htm?27/27/28091\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Single chamber pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early pacemakers were designed to sense and pace in a single chamber. Ventricular pacing can prevent ventricular bradyarrhythmias or asystole of any etiology. Atrial pacing can be used in patients with isolated sinus node dysfunction or sick sinus syndrome (SSS) and intact AV conduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     VVI or VVIR pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular demand pacing (ventricle paced, ventricle sensed, and pacemaker inhibited in response to a sensed beat) remains the most commonly used pacing mode. Advantages of ventricular demand pacing include the requirement for only a single lead and the ability to protect the patient from dangerous bradycardias of any etiology. However, ventricular demand pacing cannot maintain AV synchrony, and lack of AV synchrony can result in pacemaker syndrome. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Pacemaker syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Virtually all devices currently in use are capable of VVIR pacing. VVIR pacing is primarily indicated in patients with chronic atrial fibrillation with a slow ventricular response.",
"   </p>",
"   <p>",
"    In contrast, in a patient with normal sinus rhythm, VVIR pacing should not be used as an excuse to forego attempts at placing an atrial lead. If sinus node function is intact, dual chamber (DDD) pacing preserves AV synchrony and maintains the patients natural heart rate response to activity. This approach is optimal and should used whenever possible. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Physiologic pacing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     AAI or AAIR pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial demand pacing (atrium paced, atrium sensed, and pacemaker inhibited in response to sensed atrial beat) is appropriate for patients with sinus node dysfunction who have intact AV nodal function. Patients with symptomatic sinus bradycardia or sinus pauses, but with an intact ability to accelerate their heart rate with exertion, can be programmed in an AAI mode. Those who cannot adequately accelerate their heart rate should have rate responsive capability available (ie, AAIR).",
"   </p>",
"   <p>",
"    As with ventricular demand pacemakers, these devices have the benefit of requiring only a single lead. However, unlike ventricular single-chamber pacemakers, they will not protect patients from ventricular bradyarrhythmias due to AV conduction block. Due to this limitation, atrial demand pacemakers are infrequently used. Many clinicians are concerned that a patient who already has sinus node disease will later develop AV conduction disease. Although it would be uncommon for AV block to develop precipitously and result in a catastrophic event, gradual development of AV conduction system disease may require upgrade of the pacemaker to a dual chamber device. Pacemaker upgrade can be technically more difficult than original placement of a dual chamber pacemaker, and the second procedure obviously entails additional cost and patient risk.",
"   </p>",
"   <p>",
"    However, if the patient with sinus node dysfunction is assessed carefully and does not have AV node disease at the time of pacemaker implant, the occurrence of clinically significant AV nodal disease is very low (less than 2 percent per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/7\">",
"     7",
"    </a>",
"    ]. Assessment prior to use of an AAI system should include incremental atrial pacing at the time of pacemaker implant. Although criteria vary among institutions and implanting clinicians, the adult patient should be capable of 1:1 AV nodal conduction to rates of 120 to 140",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    Patients who are chronotropically incompetent can be programmed in the AAIR mode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Dual chamber pacing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     DDD or DDDR pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dual chamber (DDD) pacing system provides physiologic pacing (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Physiologic pacing'",
"    </a>",
"    below), with sensing and pacing capabilities in both the atrium and the ventricle.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pacemaker will be totally inhibited in the presence of sinus rhythm with normal AV conduction if the sinus rate is faster than the programmed lower rate of the pacemaker and the intrinsic AV conduction is faster than the programmed AV interval.",
"     </li>",
"     <li>",
"      If there is sinus bradycardia but normal AV conduction with the intrinsic QRS occurring before the end of the programmed AV interval, there will be atrial pacing with a native QRS complex following each paced atrial beat.",
"     </li>",
"     <li>",
"      Both the atrium and ventricle will be paced if there is sinus bradycardia and delayed or absent AV conduction.",
"     </li>",
"     <li>",
"      The ventricle will be paced synchronously with the atrium if there is normal sinus rhythm with delayed or absent AV conduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, there are four different rhythms that can be seen with normal pacemaker function (",
"    <a class=\"graphic graphic_waveform graphicRef52858 \" href=\"UTD.htm?8/46/8941\">",
"     waveform 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal sinus rhythm",
"     </li>",
"     <li>",
"      Atrial pacing, normally conducted to the ventricle with a native QRS",
"     </li>",
"     <li>",
"      AV sequential pacing",
"     </li>",
"     <li>",
"      Atrial sensing and ventricular pacing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The DDD pacing mode is appropriate for patients with AV block who have normal sinus node function. DDD pacing is also considered by some to be the mode of choice in carotid sinus hypersensitivity with symptomatic cardioinhibition. However, most patients should receive a pacemaker capable of DDDR pacing, even if rate-response is not initially programmed \"on\".",
"   </p>",
"   <p>",
"    The ideal patient for DDDR pacing is one with combined sinus nodal and AV nodal dysfunction in whom DDDR pacing would restore rate responsiveness and AV synchrony. DDDR pacing is also appropriate for patients with sinus node dysfunction and normal AV conduction. As noted above, many practitioners are not comfortable with AAIR pacing. Use of DDDR pacing mode with an algorithm that will minimize ventricular pacing is often preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     DDI or DDIR pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the DDI pacing mode, there is atrial sensing and pacing, and ventricular sensing and pacing; however, the pacemaker will not track intrinsic atrial activity. When there is a sensed native atrial rate, the pacemaker will inhibit both atrial and ventricular output, thereby allowing native conduction to the ventricle. If AV block develops, ventricular pacing will occur at a programmed rate, but will not be synchronized with the atrium.",
"   </p>",
"   <p>",
"    As an example, if a device is programmed DDI at 50 beats per minute, and the patient has sinus rhythm at 60 with 1:1 AV conduction, the device will be fully inhibited. If AV block develops, the pacemaker will pace the ventricle at 50 beats per minute. If sinus bradycardia develops, the pacemaker will pace the atrium and ventricle synchronously at 50 beats per minute.",
"   </p>",
"   <p>",
"    In the DDI mode, if the sinus rate is below the programmed rate, the pacemaker will pace the atrium and ventricle sequentially.",
"   </p>",
"   <p>",
"    There are few, if any, advantages of DDI or DDIR pacing at this time. At one time, this mode was helpful for the patient with atrial tachyarrhythmias. Since DDI does not \"track,\" this mode would alleviate the concern of fast ventricular rates in response to the atrial tachyarrhythmia. However, this has become much less important since essentially all dual-chamber devices now have mode switching capability. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Mode switching'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Less common modes",
"    </span>",
"    &nbsp;&mdash;&nbsp;VDD and DVI mode remain available options in most new pacemakers, but are rarely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6312266\">",
"    <span class=\"h4\">",
"     VDD pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;VDD pacing (ventricle paced, atrium and ventricle sensed, and either inhibition or tracking of the pacemaker in response to a sensed beat) may be appropriate for the patient with normal sinus node function and conduction disease of the AV node. Dual chamber (two lead) VDD pacing systems have largely been supplanted by DDD pacemakers.",
"   </p>",
"   <p>",
"    However, a single-lead VDD pacing system, now available for many years, has increased interest in the use of VDD as the initial pacing mode in patients with AV block but normal sinus node function [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In these systems, atrial sensing is accomplished from \"floating\" sensing electrodes on the atrial portion of the ventricular pacing lead.",
"   </p>",
"   <p>",
"    One limitation to the use of a single lead VDD pacemaker is that patients with initially normal SA node function may develop sinus node dysfunction. This would then require a second procedure to place an atrial lead capable of pacing in order to maintain AV synchrony and chronotropic competence. However, this is an infrequent occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6312283\">",
"    <span class=\"h4\">",
"     DVI pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;DVI pacemakers (atrium and ventricle paced, ventricular sensing only, and inhibition of pacemaker in response to sensed ventricular beat) were at one time implanted in large numbers of patients, often with a very satisfactory outcome, but this mode is now of historical interest only. DVI pacing is, by definition, limited by the absence of atrial sensing, which prevents the restoration of rate-responsiveness in the chronotropically competent patient. In addition, lack of atrial sensing may lead to competitive atrial pacing and initiation of atrial rhythm disturbances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Asynchronous pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacemakers may be programmed to pace at a fixed rate, without attempting to sense or react to native cardiac activity. These modes are referred to as asynchronous pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     AOO, VOO, or DOO mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;In these modes, the atrium, ventricle, or both are paced, but the pacemaker has no sensing capability and hence there is no sensing response of the pacemaker.",
"   </p>",
"   <p>",
"    Asynchronous pacing modes are rarely used long-term. These modes, however, may be temporarily necessary for patients who are undergoing a surgical procedure, especially if the patient is pacemaker-dependent. Electrocautery could be sensed by the pacemaker and misinterpreted as native cardiac activity, thereby inhibiting pacing output. This could produce significant bradycardia or asystole in a pacemaker-dependent patient.",
"   </p>",
"   <p>",
"    Thus, prior to surgery, the pacemaker could be reprogrammed to an asynchronous mode that turns off its sensing capability. After surgery, the pacemaker should be reprogrammed to its prior mode. Alternatively, a magnet placed over the pacemaker will deactivate its ability to sense and, while left in place, will result in asynchronous pacing. Although this approach has been used for many years there are some concerns that are likely more theoretical than real.",
"   </p>",
"   <p>",
"    Pacing in an asynchronous mode can be associated with competition between the native and the paced rhythms, with the possibility that a paced impulse will occur during a native T wave (or the vulnerable period). To reduce this risk, asynchronous pacing could be programmed to a relatively higher rate (&ge;80",
"    <span class=\"nowrap\">",
"     beats/min).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC PACING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic pacing is a term that is used to describe pacing systems that most closely approximate normal cardiac behavior. It most commonly refers to systems that maintain AV synchrony (eg, AAI or DDD systems, in contrast to VVI systems), but has also been applied to rate responsive pacemakers. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Rate responsiveness'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Potential advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic pacing has several potential hemodynamic and clinical advantages compared to VVI pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/13\">",
"     13",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced incidence of atrial fibrillation (AF) &mdash; The incidence of atrial tachyarrhythmias, particularly AF, is reduced by physiologic compared to VVI pacing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5367?source=see_link\">",
"       \"The role of pacemakers in the prevention of atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduced incidence of thromboembolic events &mdash; A lower rate of thromboembolic events is suggested in the meta-analysis of physiologic pacing discussed below, and may be secondary to the lower incidence of AF [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improved hemodynamics &mdash; The maintenance of AV synchrony and \"atrial kick\" is hemodynamically favorable and physiologic pacing improves cardiac output, arterial pressure, and coronary blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/15-18\">",
"       15-18",
"      </a>",
"      ]. The magnitude of these improvements is small, and their clinical significance is not clear but, in some studies, physiologic pacing has resulted in a lower incidence of heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link&amp;anchor=H7#H7\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Atrial systole'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoidance of pacemaker syndrome &mdash; VVI pacing is associated with the development of \"pacemaker syndrome.\" This syndrome is due to AV dyssynchrony or retrograde ventricular-to-atrial conduction. It is prevented by physiologic pacing [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Pacemaker syndrome'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Effect on morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials and a meta-analysis have compared physiologic and VVI pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/14,21-26\">",
"     14,21-26",
"    </a>",
"    ]. In the aggregate, these reports demonstrate that across the spectrum of patients with bradycardic indications for pacemakers, physiologic pacing does not improve survival or the incidence of heart failure, but does reduce the incidence of atrial fibrillation (AF) and may reduce the incidence of stroke.",
"   </p>",
"   <p>",
"    The meta-analysis included data from five randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Danish trial of 225 patients with sick sinus syndrome (SSS) and normal AV conduction [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/19,22,27\">",
"       19,22,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The MOST trial of 2010 patients with SSS, 20 percent of whom also had AV conduction disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/23,28\">",
"       23,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The CTOPP trial of 2568 patients with both SSS and AV conduction disease (42 percent with SSS) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/24,26,29,30\">",
"       24,26,29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The PASE trial of 407 patients, 43 percent with SSS [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/21,31\">",
"       21,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The UKPACE trial of 2021 elderly patients, all of whom had AV conduction disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The meta-analysis included 7231 patients and over 35,000 patient-years of follow-up. The average patient age was 76. Most patients randomly assigned to physiologic pacing received a dual chamber (DDD) pacemaker, while all of those in the Danish trial and some in CTOPP received an AAI pacemaker. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in the incidence of heart failure or in all-cause mortality between physiologic and VVI pacing (31 versus 33 percent all-cause mortality).",
"     </li>",
"     <li>",
"      Physiologic pacing significantly reduced the incidence of AF (17 versus 22 percent).",
"     </li>",
"     <li>",
"      Physiologic pacing appeared to reduce the incidence of stroke (5.2 versus 6.3 percent). However, the authors suggested cautious interpretation of this finding, due to borderline statistical significance (95% CI 0.67 to 0.99, p = 0.035) and the lack of adjustment for multiple hypothesis testing.",
"     </li>",
"     <li>",
"      Subgroup analysis suggested that physiologic pacing may be more beneficial in patients with SSS than those with AV block. Among patients with SSS, physiologic pacing appeared to reduce the combined endpoint of stroke or cardiovascular death. However, the authors suggested caution in the interpretation of this subgroup analysis, because of heterogeneity in the populations of the included trials (ie, different percentages of patients with SSS). Issues specifically related to physiologic pacing and SSS are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of the sick sinus syndrome\", section on 'Physiologic pacing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There was no additional advantage in several other subgroups that are often considered to derive a greater benefit from physiologic pacing (eg, those with left ventricular dysfunction or heart failure).",
"     </li>",
"     <li>",
"      Patients appear to prefer physiologic pacing, suggested by relatively high crossover rates from VVI to dual chamber pacing in the two trials in which this was easy to do. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Patient preference'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of the meta-analysis are broadly consistent with those of the individual trials. However, due to the some differences in the patient populations (eg, SSS versus AV block, elderly patients), and the pacemakers used (eg, AAI versus DDD), some points from individual studies are worth consideration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in the subgroup analysis, results from the Danish trial suggested a greater benefit of physiologic pacing in patients with SSS than in those with AV block [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of the sick sinus syndrome\", section on 'Physiologic pacing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the very elderly, the rates of AF and stroke are high regardless of pacing mode. The value of physiologic pacing may be less significant in this group, particularly those with AV block [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/25,32\">",
"       25,32",
"      </a>",
"      ]. This was best illustrated in the UKPACE trial of 2021 elderly patients (average age 80), all of whom had AV block [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/25\">",
"       25",
"      </a>",
"      ]. In this population, physiologic pacing did not reduce the rates of mortality, AF, or thromboembolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pacemaker syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacemaker syndrome is a phenomenon associated with the loss of AV synchrony due to single-chamber VVI pacing. It is defined as the adverse hemodynamics associated with a normally functioning pacing system, resulting in overt symptoms or limitation of the patient's ability to achieve optimal functional status [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/20\">",
"     20",
"    </a>",
"    ]. The development of the pacemaker syndrome with VVI pacing may require upgrade from a VVI pacemaker to a dual chamber system in some patients.",
"   </p>",
"   <p>",
"    The syndrome is characterized by a decrease in stroke volume, and probable atrial contraction against a closed AV valve, similar to what is seen during complete heart block. Symptoms include presyncope or syncope, easy fatigability, cough, dizziness, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and a sensation of throat fullness. Physical examination may reveal hypotension, rales, increased jugular venous pressure with cannon A waves, peripheral edema, and murmurs of tricuspid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/20,33\">",
"     20,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Patient preference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no consistent mortality benefit has been identified in randomized clinical trials with physiologic pacing, patients seem to prefer physiologic pacing as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind crossover study of different pacing modes, 86 percent of patients preferred physiologic pacing [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In PASE and MOST, quality of life scores were higher in patients with sick sinus syndrome (SSS) randomly assigned to physiologic pacing [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/21,23\">",
"       21,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the clinical trials comparing physiologic and VVI pacing, when crossing over from VVI to physiologic pacing was easy, up to 38 percent of patients chose to cross over. In PASE and MOST, all patients received dual chamber pacemakers, and randomization to physiologic or VVI pacing occurred after implantation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/21,23\">",
"       21,23",
"      </a>",
"      ]. Thus, crossover required only device reprogramming (as opposed to a second procedure). The crossover rates in these two trials were 26 and 38 percent (compared to less than 5 percent in the other trials).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The high crossover rate in MOST has led to questions about the validity of the results. However, in a later study, the results of intention-to-treat and on-treatment analyses were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/28\">",
"     28",
"    </a>",
"    ]. As in the original report from MOST [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/23\">",
"     23",
"    </a>",
"    ], the on-treatment analysis showed no difference in the primary endpoint between the two pacing modes, but there was a significant reduction in the incidence of atrial fibrillation with physiologic pacing.",
"   </p>",
"   <p>",
"    Based upon the reduced incidence of atrial fibrillation and patient preference, we suggest that physiologic pacing should be used in most patients who require a pacemaker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MODE SELECTION ALGORITHMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of guidelines and algorithms are available for determining the appropriate pacing mode for patients with sinus node disease and AV node disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications and contraindications for the various types of pacing modes are listed in the accompanying tables (",
"    <a class=\"graphic graphic_table graphicRef76319 graphicRef55317 graphicRef69138 \" href=\"UTD.htm?2/58/2990\">",
"     table 4A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1849/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In this listing, chronotropically competent refers to the ability of a patient to achieve an appropriate heart rate for a given physiologic activity.",
"   </p>",
"   <p>",
"    Several algorithms are also available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General algorithms for all bradycardic indications (",
"      <a class=\"graphic graphic_algorithm graphicRef64626 \" href=\"UTD.htm?34/8/34958\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef76446 \" href=\"UTD.htm?10/19/10557\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An algorithm for sick sinus syndrome (",
"      <a class=\"graphic graphic_algorithm graphicRef77929 \" href=\"UTD.htm?11/60/12239\">",
"       algorithm 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An algorithm for AV block (",
"      <a class=\"graphic graphic_figure graphicRef71370 \" href=\"UTD.htm?28/21/29023\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=see_link\">",
"       \"Patient information: Pacemakers (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=see_link\">",
"       \"Patient information: Pacemakers (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the selection of pacemakers for implantation in patients with a standard bradycardic indication for pacing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients can be managed with one of three common pacing modes (with or without rate responsive pacing): AAI(R), VVI(R), or DDD(R). At the time of implantation, one should consider how many leads will be necessary and which additional features, if any, will be of potential value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Single or dual chamber pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important choice in most patients is whether to place a single or dual chamber pacemaker. The choice varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with chronic atrial fibrillation (AF) who require a pacemaker due to slow ventricular response, we recommend a single chamber ventricular pacemaker (VVI or VVIR) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with conditions that could be managed with either a single or a dual chamber pacemaker (eg, AV block, SSS), we suggest physiologic pacing with a dual chamber pacemaker (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Physiologic pacing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single-chamber pacemaker is a reasonable alternative in patients who are very elderly or whose anatomy and physical condition make the implantation of two leads more difficult than usual. In such cases, the additional costs and risks of a dual chamber physiologic pacemaker may outweigh the potential benefits of the reduced risk of AF and patient preference.",
"   </p>",
"   <p>",
"    VVI(R) pacing will be effective in all such patients. An AAI(R) pacemaker is a reasonable alternative to VVI(R) pacing in the subset of patients with SSS in whom AV conduction is intact and meets intra-implant testing criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Additional features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following additional features are appropriate for selected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rate responsiveness can be programmed for patients who are active, but not chronotropically competent. This feature is available in most contemporary devices. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Rate responsiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mode switching can be programmed for patients with paroxysmal atrial arrhythmias. This feature is available in most contemporary devices. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Mode switching'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rate drop may be appropriate for some patients with neurocardiogenic syncope. This feature is not available in all devices. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rate drop'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular avoidance pacing algorithms are appropriate for most patients with PR prolongation or type II AV block. Some parameter to minimize ventricular pacing is available in most contemporary devices. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Modes to minimize ventricular pacing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/1\">",
"      Bernstein AD, Daubert JC, Fletcher RD, et al. The revised NASPE/BPEG generic code for antibradycardia, adaptive-rate, and multisite pacing. North American Society of Pacing and Electrophysiology/British Pacing and Electrophysiology Group. Pacing Clin Electrophysiol 2002; 25:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/2\">",
"      Kamalvand K, Tan K, Kotsakis A, et al. Is mode switching beneficial? A randomized study in patients with paroxysmal atrial tachyarrhythmias. J Am Coll Cardiol 1997; 30:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/3\">",
"      Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol 2006; 47:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/4\">",
"      Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med 2007; 357:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/5\">",
"      Sweeney MO, Ellenbogen KA, Casavant D, et al. Multicenter, prospective, randomized safety and efficacy study of a new atrial-based managed ventricular pacing mode (MVP) in dual chamber ICDs. J Cardiovasc Electrophysiol 2005; 16:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/6\">",
"      Olshansky B, Day JD, Moore S, et al. Is dual-chamber programming inferior to single-chamber programming in an implantable cardioverter-defibrillator? Results of the INTRINSIC RV (Inhibition of Unnecessary RV Pacing With AVSH in ICDs) study. Circulation 2007; 115:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/7\">",
"      Hayes DL, Furman S. Stability of AV conduction in sick sinus node syndrome patients with implanted atrial pacemakers. Am Heart J 1984; 107:644.",
"     </a>",
"    </li>",
"    <li>",
"     Antonioli, G, Ansani, L, Barbieri, D, et al. Single-Lead VDD Pacing. In: New Perspectives in Cardiac Pacing, 3, Barold, S, Mugica, J (Eds), Futura Publishing, Mount Kisco 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/9\">",
"      Rey JL, Tribouilloy C, Elghelbazouri F, Otmani A. Single-lead VDD pacing: long-term experience with four different systems. Am Heart J 1998; 135:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/10\">",
"      Huang M, Krahn AD, Yee R, et al. Optimal pacing for symptomatic AV block: a comparison of VDD and DDD pacing. Pacing Clin Electrophysiol 2004; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/11\">",
"      Wiegand UK, Bode F, Schneider R, et al. Development of sinus node disease in patients with AV block: implications for single lead VDD pacing. Heart 1999; 81:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/12\">",
"      Morsi A, Lau C, Nishimura S, Goldman BS. The development of sinoatrial dysfunction in pacemaker patients with isolated atrioventricular block. Pacing Clin Electrophysiol 1998; 21:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/13\">",
"      Lamas GA, Ellenbogen KA. Evidence base for pacemaker mode selection: from physiology to randomized trials. Circulation 2004; 109:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/14\">",
"      Healey JS, Toff WD, Lamas GA, et al. Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. Circulation 2006; 114:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/15\">",
"      Stewart WJ, Dicola VC, Harthorne JW, et al. Doppler ultrasound measurement of cardiac output in patients with physiologic pacemakers. Effects of left ventricular function and retrograde ventriculoatrial conduction. Am J Cardiol 1984; 54:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/16\">",
"      Rediker DE, Eagle KA, Homma S, et al. Clinical and hemodynamic comparison of VVI versus DDD pacing in patients with DDD pacemakers. Am J Cardiol 1988; 61:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/17\">",
"      Boon NA, Frew AJ, Johnston JA, Cobbe SM. A comparison of symptoms and intra-arterial ambulatory blood pressure during long term dual chamber atrioventricular synchronous (DDD) and ventricular demand (VVI) pacing. Br Heart J 1987; 58:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/18\">",
"      Takeuchi M, Nohtomi Y, Kuroiwa A. Effect of ventricular pacing on coronary blood flow in patients with normal coronary arteries. Pacing Clin Electrophysiol 1997; 20:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/19\">",
"      Nielsen JC, Andersen HR, Thomsen PE, et al. Heart failure and echocardiographic changes during long-term follow-up of patients with sick sinus syndrome randomized to single-chamber atrial or ventricular pacing. Circulation 1998; 97:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/20\">",
"      Ausubel K, Furman S. The pacemaker syndrome. Ann Intern Med 1985; 103:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/21\">",
"      Lamas GA, Orav EJ, Stambler BS, et al. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med 1998; 338:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/22\">",
"      Andersen HR, Thuesen L, Bagger JP, et al. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet 1994; 344:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/23\">",
"      Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002; 346:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/24\">",
"      Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med 2000; 342:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/25\">",
"      Toff WD, Camm AJ, Skehan JD, United Kingdom Pacing and Cardiovascular Events Trial Investigators. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med 2005; 353:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/26\">",
"      Kerr CR, Connolly SJ, Abdollah H, et al. Canadian Trial of Physiological Pacing: Effects of physiological pacing during long-term follow-up. Circulation 2004; 109:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/27\">",
"      Andersen HR, Nielsen JC, Thomsen PE, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet 1997; 350:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/28\">",
"      Hellkamp AS, Lee KL, Sweeney MO, et al. Treatment crossovers did not affect randomized treatment comparisons in the Mode Selection Trial (MOST). J Am Coll Cardiol 2006; 47:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/29\">",
"      Skanes AC, Krahn AD, Yee R, et al. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001; 38:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/30\">",
"      Tang AS, Roberts RS, Kerr C, et al. Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. Circulation 2001; 103:3081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/31\">",
"      Ellenbogen KA, Stambler BS, Orav EJ, et al. Clinical characteristics of patients intolerant to VVIR pacing. Am J Cardiol 2000; 86:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/32\">",
"      Jahangir A, Shen WK, Neubauer SA, et al. Relation between mode of pacing and long-term survival in the very elderly. J Am Coll Cardiol 1999; 33:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/33\">",
"      Link MS, Hellkamp AS, Estes NA 3rd, et al. High incidence of pacemaker syndrome in patients with sinus node dysfunction treated with ventricular-based pacing in the Mode Selection Trial (MOST). J Am Coll Cardiol 2004; 43:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/34\">",
"      Sulke N, Chambers J, Dritsas A, Sowton E. A randomized double-blind crossover comparison of four rate-responsive pacing modes. J Am Coll Cardiol 1991; 17:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/35\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1849/abstract/36\">",
"      Kusumoto FM, Goldschlager N. Cardiac pacing. N Engl J Med 1996; 334:89.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 950 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1849=[""].join("\n");
var outline_f1_51_1849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Five position code",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Position I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Position II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Position III",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Position IV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Position V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mode switching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Rate responsiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rate drop",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Modes to minimize ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Biventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PACING MODES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Single chamber pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - VVI or VVIR pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - AAI or AAIR pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Dual chamber pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - DDD or DDDR pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - DDI or DDIR pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Less common modes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6312266\">",
"      VDD pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6312283\">",
"      DVI pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Asynchronous pacing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - AOO, VOO, or DOO mode",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PHYSIOLOGIC PACING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Potential advantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Effect on morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pacemaker syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Patient preference",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MODE SELECTION ALGORITHMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Single or dual chamber pacemakers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Additional features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/950|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/8/34958\" title=\"algorithm 1\">",
"      Pacemaker algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/60/12239\" title=\"algorithm 2\">",
"      Pacemaker algorithm sinus node dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/950|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/19/10557\" title=\"figure 1\">",
"      Pacemaker algorithm rate adaptive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/21/29023\" title=\"figure 2\">",
"      Pacemaker algorithm AV block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/36/13900\" title=\"table 1\">",
"      Guidelines pacemaker type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/46/1772\" title=\"table 2\">",
"      NBG code pacing nomenclature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/27/28091\" title=\"table 3\">",
"      Ventricular and atrial pacers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/55/3964\" title=\"table 4A\">",
"      Indications pacing modes I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/13/43227\" title=\"table 4B\">",
"      Indications pacing modes II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/6/20588\" title=\"table 4C\">",
"      Indications pacing modes III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/950|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?8/46/8941\" title=\"waveform 1\">",
"      Rhythms with DDD pacemaker",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31510?source=related_link\">",
"      Overview of cardiac pacing in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/16/20741?source=related_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5367?source=related_link\">",
"      The role of pacemakers in the prevention of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_51_1850="Noninvasive positive pressure ventilation in acute respiratory failure in adults";
var content_f1_51_1850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1850/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1850/contributors\">",
"     Kristy A Bauman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1850/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1850/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/51/1850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/51/1850/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/51/1850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (NPPV) refers to positive pressure ventilation delivered through a noninvasive interface (nasal mask, facemask, or nasal plugs), rather than an invasive interface (endotracheal tube, tracheostomy). Its use has become more common as its benefits are increasingly recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of mechanical ventilation\", section on 'Types of breaths'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of NPPV for acute respiratory failure is discussed here, including its indications, contraindications, benefits, and potential harms. Initiation and weaning of NPPV are also reviewed. NPPV for neuromuscular disorders, chest wall disease, or obesity hypoventilation syndrome is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=see_link\">",
"     \"Noninvasive positive pressure therapy of the obesity hypoventilation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=see_link\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=see_link\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selecting patients for NPPV requires careful consideration of its indications and contraindications, which are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial of NPPV is worthwhile in most patients who do not require emergent intubation and have a disease known to respond to NPPV, assuming that they lack contraindications [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/3\">",
"     3",
"    </a>",
"    ]. This is especially true for patients who have features that predict success using NPPV (",
"    <a class=\"graphic graphic_table graphicRef59165 \" href=\"UTD.htm?9/17/9499\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Conditions known to respond to NPPV include exacerbations of chronic obstructive pulmonary disease (COPD) that are complicated by hypercapnic acidosis (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;45 mmHg or pH &lt;7.30), cardiogenic pulmonary edema, and hypoxemic respiratory failure. NPPV may also be helpful for preventing post-extubation respiratory failure. Despite evidence of efficacy, NPPV may be underutilized among patients with cardiogenic pulmonary edema or hypercapnic COPD exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Benefits'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for emergent intubation is an absolute contraindication to NPPV. In addition, there are numerous relative contraindications to NPPV (",
"    <a class=\"graphic graphic_table graphicRef60442 \" href=\"UTD.htm?16/54/17259\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac or respiratory arrest",
"     </li>",
"     <li>",
"      Inability to cooperate, protect the airway, or clear secretions",
"     </li>",
"     <li>",
"      Severely impaired consciousness",
"     </li>",
"     <li>",
"      Nonrespiratory organ failure",
"     </li>",
"     <li>",
"      Facial surgery, trauma, or deformity",
"     </li>",
"     <li>",
"      High aspiration risk",
"     </li>",
"     <li>",
"      Prolonged duration of mechanical ventilation anticipated",
"     </li>",
"     <li>",
"      Recent esophageal anastomosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypercapnic encephalopathy may be an exception to the rule that severely impaired consciousness is a contraindication to NPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Clinicians who choose to try NPPV in this setting should monitor such patients closely. Improved consciousness should be apparent within 1 to 2 hours after the initiation of NPPV. Patients who deteriorate or fail to improve should be promptly intubated. The likelihood that hypercapnic encephalopathy will respond to NPPV is inversely related to the severity of the hypercapnia. Respiratory acidosis is NOT a contraindication to NPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with one or more contraindications should forgo a trial of NPPV. Instead, they should be intubated and undergo invasive mechanical ventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     INITIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient has been selected to receive a trial of NPPV, it should be initiated as soon as possible. Delays may allow further deterioration and increase the likelihood of failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ventilator type",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPPV can be delivered via the standard type of ventilator found in most intensive care units (ICUs) or a portable ventilator. However, the standard ICU ventilator has numerous advantages [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A precise concentration of oxygen can be delivered",
"     </li>",
"     <li>",
"      High concentrations of oxygen can be delivered",
"     </li>",
"     <li>",
"      Separate inspiratory and expiratory tubing minimizes the rebreathing of carbon dioxide (CO",
"      <sub>",
"       2",
"      </sub>",
"      )",
"     </li>",
"     <li>",
"      Large mask leaks",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      patient disconnection are more readily detected",
"     </li>",
"     <li>",
"      Better monitoring and alarm features",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, certain modes can only be delivered with a standard ICU ventilator (eg, time-limited pressure support ventilation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interface",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient-ventilator interfaces available for NPPV include a face mask, nasal mask, and nasal plugs. These interfaces were compared in a trial that randomly assigned 26 patients with a COPD exacerbation complicated by hypercapnia to receive NPPV via full face mask, nasal mask, or nasal plugs [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/15\">",
"     15",
"    </a>",
"    ]. The face mask conferred the greatest physiologic improvement, but the nasal mask was best tolerated. A similar study found that more than one-half of patients initially treated using a nasal mask needed to be changed to a face mask [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/16\">",
"     16",
"    </a>",
"    ]. This was usually due to a significant air leak through the mouth.",
"   </p>",
"   <p>",
"    The face mask is generally preferred over a nasal mask or nasal prongs during the initiation of NPPV for several reasons (",
"    <a class=\"graphic graphic_table graphicRef55475 \" href=\"UTD.htm?4/3/4156\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients with acute respiratory failure are mouth breathers; therefore, NPPV delivered by a nasal mask results in a large air leak through the mouth and a worse outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The nasal air passages offer significant resistance to airflow, which can mitigate the beneficial effects of NPPV if a low level of positive airway pressure is used [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/12,18\">",
"       12,18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the primary disadvantage of the facial mask is that monitoring for aspiration is more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A helmet interface has been developed that improves patient tolerance, an important factor in the success of NPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The helmet interface allows patients to talk, read, and drink through a straw, while minimizing complications such as skin necrosis, gastric distension, and eye irritation. Drawbacks of the helmet device include the accumulation of CO",
"    <sub>",
"     2",
"    </sub>",
"    within the helmet (alleviated by increasing gas flow rates), a level of noise exposure sufficiently high to cause hearing damage, more patient-ventilator asynchrony, and less relief of inspiratory effort [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the interface chosen, heated humidification brings the relative humidity back toward the ambient range. This enhances patient comfort [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPPV can be delivered using the same modes that are used for invasive mechanical ventilation, although certain modes are used more frequently:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assist control (AC) is the most common mode chosen by clinicians who want a guaranteed minimal minute ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H5#H5\">",
"       \"Modes of mechanical ventilation\", section on 'AC'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pressure support ventilation (PSV) is the most common mode chosen by clinicians who want to maximize patient comfort and synchrony. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H11#H11\">",
"       \"Modes of mechanical ventilation\", section on 'Pressure support'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continuous positive airway pressure (CPAP) is often used for patients with acute respiratory failure due to cardiogenic pulmonary edema, for reasons discussed below. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H15#H15\">",
"       \"Modes of mechanical ventilation\", section on 'Continuous positive airway pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bilevel positive airway pressure (BPAP) delivers both inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). The terms \"BiPAP\" and \"BIPAP\" are often used incorrectly to refer to NPPV in the BPAP mode. BiPAP&reg; is a specific type of BPAP delivered by a portable ventilator manufactured by the Respironics Corporation, while BIPAP&reg; is a specific type of BPAP delivered by a ventilator made by the Drager Medical Company. These are just two of the ventilators that can deliver BPAP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H16#H16\">",
"       \"Modes of mechanical ventilation\", section on 'Bilevel positive airway pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Proportional assist ventilation (PAV) delivers an inspiratory pressure that is proportional to patient effort. Specifically, it is determined by patient-generated volume and flow. PAV provides automatic synchrony between the patient and the ventilatory cycle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Controlled mechanical ventilation (CMV), intermittent mandatory ventilation (IMV), synchronized intermittent mandatory ventilation (SIMV), and pressure controlled ventilation (PCV) are seldom used during NPPV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials that compared standard therapy alone to standard therapy plus NPPV in patients with acute respiratory failure found that NPPV improved outcomes when any of the following modes were used: AC [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/28\">",
"     28",
"    </a>",
"    ], PSV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/29\">",
"     29",
"    </a>",
"    ], or BPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. Relatively few studies have directly compared NPPV modes in patients with acute respiratory failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute respiratory failure due to a variety of causes &ndash; Three randomized trials demonstrated that PAV and PSV had similar impact on intubation rates and mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/34-36\">",
"       34-36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute respiratory failure due to COPD exacerbations &ndash; Two randomized trials found that AC reduced the work of breathing more than PSV, but PSV was better tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/37,38\">",
"       37,38",
"      </a>",
"      ], while two observational studies found that BPAP improved gas exchange and reduced the work of breathing more effectively than PSV [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute respiratory failure due to cardiogenic pulmonary edema &ndash; A meta-analysis (23 randomized trials) found no difference in mortality when BPAP and CPAP were directly compared [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/41\">",
"       41",
"      </a>",
"      ]. Both BPAP and CPAP reduced mortality and the intubation rate compared to standard therapy. Similarly, a randomized trial that compared PSV to CPAP found no difference in either mortality or the frequency of intubations, although respiratory distress appeared to resolve sooner among patients who received PSV [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Asynchrony",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients do not tolerate NPPV. This is often due to patient-ventilator asynchrony (ie, the phases of ventilator breath do not match that of the patient) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of mechanical ventilation\", section on 'Asynchrony'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PSV tends to be a comfortable mode and may minimize asynchrony. It allows the patient to trigger each breath and independently regulate the depth and pattern of breathing. It is reasonable to expect that BPAP provides a similar level of comfort, although this has not been studied.",
"   </p>",
"   <p>",
"    PAV may be helpful in patients who do not tolerate PSV or BPAP. It has the advantage of having an inspiratory flow and delivered volume that is proportional to the patient's effort. Cessation of inspiration is determined entirely by the patient, allowing the patient to control the entire respiratory cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/45\">",
"     45",
"    </a>",
"    ]. Three randomized trials compared PAV to PSV in patients with acute respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Each found that PAV was more comfortable and better tolerated than PSV. However, there was no difference in mortality or intubation rates.",
"   </p>",
"   <p>",
"    The mode is not the only consideration when patient-ventilator asynchrony exists: the possibility of a mask leak should always be investigated. A mask leak can increase the time required for the ventilator to achieve its pressure target, prolonging inspiration and causing discomfort. Having the PSV time-limited (rather than flow-limited) can improve this situation, although only certain ventilators are capable of delivering time-limited PSV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selected mode determines which parameters need to be set during the initiation of NPPV. As an example, AC requires that a tidal volume, respiratory rate, inspiratory flow rate, applied PEEP, and fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) be set. The parameters that need to be set for each mode are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial settings for NPPV are similar to those for invasive positive pressure ventilation. These are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of mechanical ventilation\", section on 'Initiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A universal approach to establishing the initial settings for NPPV has not been established. One reasonable protocol for initiating BPAP is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef51201 \" href=\"UTD.htm?1/8/1164\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;After NPPV is initiated, the patient should be observed closely for the first eight hours to troubleshoot, provide reassurance, and monitor for deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/32\">",
"     32",
"    </a>",
"    ]. Improvement of the pH and arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) within one-half to two hours predicts success [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/17,39\">",
"     17,39",
"    </a>",
"    ]. In contrast, a patient should be considered to have failed NPPV and promptly intubated if there is neither stabilization nor improvement over the same time frame. Other criteria suggesting failure are worse encephalopathy or agitation, inability to clear secretions, inability to tolerate any of the interfaces, hemodynamic instability, or decreased oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the ability of clinicians to select patients with a high likelihood of success is poor and NPPV failure rates are high [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/39,47,48\">",
"     39,47,48",
"    </a>",
"    ]. Two observational studies found that approximately one-third of patients who received a trial of NPPV failed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     WEANING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weaning from NPPV may be accomplished by progressively decreasing the amount of positive airway pressure, permitting the patient to be disconnected from the NPPV for progressively longer durations, or a combination of both [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of NPPV on mortality, nosocomial infection, and the need for invasive mechanical ventilation has been studied in heterogeneous populations of patients with acute respiratory failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality &mdash; First-line treatment with NPPV is associated with lower mortality than first-line treatment with invasive mechanical ventilation (23 versus 39 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/52\">",
"       52",
"      </a>",
"      ]. It is unknown whether this is a consequence of selection bias (ie, less sick patients receive a trial of NPPV), fewer complications related to intubation (eg, ventilator-associated pneumonia), or both.",
"      <br/>",
"      <br/>",
"      NPPV failure is associated with increased mortality, except for the subgroup of patients with either cardiogenic pulmonary edema or hypercapnic respiratory failure (mostly COPD). This implies that selection of patients for a trial of NPPV is critical for patients who have acute respiratory failure for reasons other than cardiogenic pulmonary edema or hypercapnic respiratory failure (mostly COPD).",
"     </li>",
"     <li>",
"      Nosocomial infection &mdash; NPPV appears to decrease the incidence of nosocomial infections [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/53-55\">",
"       53-55",
"      </a>",
"      ]. This is probably a consequence of fewer ventilator-associated pneumonias due to avoidance of intubation, as well as fewer other nosocomial infections (eg, sinusitis, line sepsis) due to a shorter length of stay and shorter duration of invasive monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intubation &mdash; NPPV in patients with acute respiratory failure also reduces the frequency of invasive mechanical ventilation. In a meta-analysis of seven randomized trials, NPPV reduced the need for invasive mechanical ventilation approximately 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These benefits were demonstrated in patients with acute respiratory failure due to a variety of causes. The magnitude of these benefits varies according to the cause of the acute respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/58\">",
"     58",
"    </a>",
"    ]. Generally speaking, the benefits of NPPV appear greatest among patients with cardiogenic pulmonary edema or a COPD exacerbation complicated by hypercapnic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     COPD exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High quality evidence (randomized trials, meta-analyses) indicates that NPPV improves important clinical outcomes in patients having an acute exacerbation of COPD complicated by hypercapnic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/29,59-61\">",
"     29,59-61",
"    </a>",
"    ]. As an example, consider a meta-analysis (14 randomized trials, 758 patients) that compared standard therapy alone to NPPV plus standard therapy in patients having a COPD exacerbation complicated by hypercapnia (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;45 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/59\">",
"     59",
"    </a>",
"    ]. NPPV decreased mortality (11 versus 21 percent), intubation rate (16 versus 33 percent), and treatment failure (20 versus 42 percent). Hospital length of stay and complications related to treatment were also reduced by NPPV.",
"   </p>",
"   <p>",
"    Patients with severe exacerbations of COPD respond better to NPPV than patients with mild COPD exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/59,60,62\">",
"     59,60,62",
"    </a>",
"    ]. This is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial randomly assigned 52 patients with mild COPD exacerbations (defined as dyspnea with a pH &gt;7.3) to receive standard therapy alone or NPPV plus standard therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/62\">",
"       62",
"      </a>",
"      ]. There were no differences in the rate of intubation or the length of hospital stay. In addition, the NPPV was tolerated by fewer than half of the patients.",
"     </li>",
"     <li>",
"      A meta-analysis (15 randomized trials) found that NPPV improved clinical outcomes only in those randomized trials that enrolled patients with severe COPD exacerbations (defined as a baseline pH &lt;7.3 or a control group mortality &gt;10 percent) and not in those trials that enrolled patients with milder COPD exacerbations [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear whether NPPV has any beneficial effects on long-term clinical outcomes. In a randomized trial that compared NPPV to invasive mechanical ventilation in 49 patients with severe COPD exacerbations, patients receiving NPPV required fewer hospital readmissions over the subsequent year, but survival rates were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, NPPV has physiologic benefits. Respiratory mechanics measured after the initiation of NPPV demonstrate a decreased respiratory rate, an increased tidal volume, and an increased minute ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/64\">",
"     64",
"    </a>",
"    ]. In addition, the arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) tends to increase as the PaCO",
"    <sub>",
"     2",
"    </sub>",
"    decreases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiogenic pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is high quality evidence from meta-analyses and randomized trials that NPPV decreases the need for intubation and improves respiratory parameters (eg, heart rate, dyspnea, hypercapnia, acidosis) in patients with cardiogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/61,65-71\">",
"     61,65-71",
"    </a>",
"    ]. Several studies suggest that NPPV may be particularly beneficial to patients with hypercarbia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is conflicting evidence regarding the impact of NPPV on mortality in patients with acute cardiogenic pulmonary edema. This evidence was summarized in a systematic review that included two meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first meta-analysis of 13 trials (1369 patients) found that patients who received continuous positive airway pressure (CPAP) plus standard care had a lower hospital mortality than those who received standard care alone (10.3 versus 15.8 percent, RR 0.64, 95% CI 0.44-0.92).",
"     </li>",
"     <li>",
"      The second meta-analysis of 9 randomized trials (1091 patients) found that patients who received bilevel positive airway pressure (BPAP) plus standard care had a nonstatistically significant lower hospital mortality than those who received standard care alone (9.6 versus 11.9 percent, RR CI 0.82, 95% CI 0.58-1.15). An important limitation of this meta-analysis is that it was too small to exclude a clinically important effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of acute decompensated heart failure is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypoxemic respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is conflicting evidence about whether NPPV is advantageous in patients with hypoxemic respiratory failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several studies suggest that NPPV is beneficial to such patients [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/30,33,55,74-76\">",
"       30,33,55,74-76",
"      </a>",
"      ]. As an example, a meta-analysis (8 randomized trials, 461 patients) compared standard medical therapy alone to standard medical therapy plus NPPV in patients with hypoxemic respiratory failure due to causes other than cardiogenic pulmonary edema [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/75\">",
"       75",
"      </a>",
"      ]. NPPV reduced ICU mortality (17 percent absolute risk reduction), intubation rate (23 percent absolute risk reduction), and ICU length of stay (2 day absolute reduction) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/75\">",
"       75",
"      </a>",
"      ]. The meta-analysis was limited by heterogeneity across the included trials.",
"     </li>",
"     <li>",
"      In contrast, an observational study that included 144 patients who received NPPV for hypoxemic respiratory failure found that 60 percent eventually required endotracheal intubation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/77\">",
"       77",
"      </a>",
"      ]. This intubation rate was higher than that reported in most randomized trials that enrolled similar patients, suggesting that NPPV may not reduce the intubation rate in such patients. Hospital mortality was also high (64 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reason for the conflicting data is uncertain but may be related to the causes of hypoxemic respiratory failure in the studies, since the benefit of NPPV appears to vary among the different causes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumonia &ndash; Difficulty managing secretions is an accepted contraindication to NPPV (",
"      <a class=\"graphic graphic_table graphicRef59165 \" href=\"UTD.htm?9/17/9499\">",
"       table 1",
"      </a>",
"      ). However, NPPV may be beneficial in patients with pneumonia if they are able to manage their secretions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/78\">",
"       78",
"      </a>",
"      ]. In one trial, 105 patients with acute hypoxemic respiratory failure of varying etiologies were randomly assigned to receive standard medical therapy alone or NPPV plus standard medical therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/30\">",
"       30",
"      </a>",
"      ]. NPPV decreased ICU mortality (18 versus 39 percent) and the intubation rate (25 versus 52 percent). These effects were particularly strong in the subgroup of patients with hypoxemic respiratory failure due to pneumonia. The outcomes of decreased ICU mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/79\">",
"       79",
"      </a>",
"      ], a decreased intubation rate [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/79,80\">",
"       79,80",
"      </a>",
"      ], and improved oxygenation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/81\">",
"       81",
"      </a>",
"      ] were also reported in separate randomized trials that enrolled patients with community-acquired pneumonia or immunosuppressed patients with pulmonary infiltrates and fever.",
"     </li>",
"     <li>",
"      Acute respiratory distress syndrome (ARDS) &ndash; There are no controlled trials and little clinical experience using NPPV to manage patients with ARDS. &nbsp;The limited evidence that exists is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H17#H17\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Invasive versus noninvasive'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have investigated the use of NPPV in severe asthma exacerbations. However, the limited evidence that exists suggests that NPPV may be beneficial.",
"   </p>",
"   <p>",
"    In one trial, 30 patients with a severe asthma exacerbation (respiratory rate &gt;30 breaths per minute, FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;60 percent of predicted when measured 30 minutes after inhaled bronchodilator therapy) were randomly assigned to receive NPPV (in the BPAP mode) or sham (subtherapeutic BPAP) in the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/82\">",
"     82",
"    </a>",
"    ]. NPPV reduced the rate of hospitalization (18 versus 63 percent) and increased the likelihood of a significant improvement in FEV",
"    <sub>",
"     1",
"    </sub>",
"    (80 versus 20 percent). The benefits found in this randomized trial were consistent with those described in several studies of lower quality (nonrandomized controlled trials, uncontrolled trials, case series), which used a variety of different modes of NPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/83-86\">",
"     83-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher quality clinical trials are needed to confirm that NPPV is beneficial to patients with severe asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/87\">",
"     87",
"    </a>",
"    ]. However, until such studies are performed, a trial of NPPV prior to invasive mechanical ventilation seems reasonable for patients having a severe asthma exacerbation despite initial bronchodilator therapy, if they do not require immediate intubation and have no contraindications to NPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Post-extubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPPV may be beneficial in preventing recurrent respiratory failure if it is initiated early. Use of NPPV in this setting is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link&amp;anchor=H8#H8\">",
"     \"Extubation management\", section on 'Post-extubation management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Immunocompromised",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence suggests that NPPV is associated with a decreased ICU mortality, intubation rate, and ICU length of stay in immunocompromised patients with acute respiratory failure, compared to invasive mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/56,79,89,90\">",
"     56,79,89,90",
"    </a>",
"    ]. These outcomes are probably a consequence of fewer nosocomial infections.",
"   </p>",
"   <p>",
"    However, not all immunocompromised patients with acute respiratory failure benefit from NPPV. Independent predictors of NPPV failure include an elevated respiratory rate during NPPV, the need for vasopressors or renal replacement therapy, and an increased duration between admission and the initiation of NPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. These predictors were identified by an observational study of 99 patients with hematologic malignancy and acute respiratory failure, during which approximately one-half of patients failed a trial of NPPV and required endotracheal intubation. The patients who failed NPPV had a higher hospital mortality, a longer duration of ICU stay, and a greater risk of nosocomial infection than those who did not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPPV has been used in other clinical settings, but the results have been variable. As a result, the following conditions are not widely accepted as a NPPV-responsive diseases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pre-intubation &mdash; Patients with hypoxemic respiratory failure are typically preoxygenated with 100 percent oxygen prior to the initiation of conventional mechanical ventilation, in order to prevent arterial oxygen desaturation during intubation. A randomized trial compared standard preoxygenation (with a bag mask valve) to preoxygenation with NPPV [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/93\">",
"       93",
"      </a>",
"      ]. The NPPV group had fewer oxyhemoglobin desaturations during intubation and a higher oxyhemoglobin saturation at the end of preoxygenation, during intubation, and five minutes after intubation.",
"     </li>",
"     <li>",
"      Intubation refusal &mdash; NPPV has been used in patients who refuse endotracheal intubation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/39,94-97\">",
"       39,94-97",
"      </a>",
"      ]. Observational studies indicate that up to 43 percent of such patients survive to hospital discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/97,98\">",
"       97,98",
"      </a>",
"      ]. However, the mortality rate during the next six months is high [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     POTENTIAL HARMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NPPV is generally safe. Complications related to positive pressure ventilation (eg, barotrauma, hemodynamic instability) tend to be less common during NPPV than invasive positive pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/99\">",
"     99",
"    </a>",
"    ]. Most complications due to NPPV are local and related to the tightly fitting mask:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local skin damage may occur due to the pressure effects of the mask and straps [",
"      <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/100\">",
"       100",
"      </a>",
"      ]. Cushioning the forehead and the bridge of the nose prior to attaching the mask can decrease the likelihood of these problems",
"     </li>",
"     <li>",
"      Modest mask leaks are common and do not preclude NPPV. A mask leak can often be remedied by using a different mask or different ventilator settings",
"     </li>",
"     <li>",
"      Eye irritation, sinus pain, or sinus congestion may occur and require either a lower inspiratory pressure or a facial mask rather than a nasal mask",
"     </li>",
"     <li>",
"      Mild gastric distention occurs frequently, but is rarely clinically significant at usual levels of inspiratory pressure. Routine use of a nasogastric tube is not warranted",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some studies have found an association between NPPV and myocardial infarction in patients with cardiogenic pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. Two meta-analysis also detected an increase in myocardial infarction risk, but the effect was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?1/51/1850/abstract/41,104\">",
"     41,104",
"    </a>",
"    ]. However, the effect would be clinically significant if real, suggesting that larger studies looking at this outcome are necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Noninvasive positive pressure ventilation (NPPV) refers to positive pressure ventilation delivered through a noninvasive interface (nasal mask, facemask, nasal plugs, or helmet). (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A trial of NPPV is worthwhile for a variety of patients. The following recommendations pertain to patients who do not require emergent intubation and lack contraindications to NPPV (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Indications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Contraindications'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with an exacerbation of chronic obstructive pulmonary disease (COPD) complicated by hypercapnic acidosis (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      &gt;45 mmHg or pH &lt;7.30) who do not require emergent intubation and lack contraindications to NPPV, we recommend a trial of NPPV (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'COPD exacerbation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute cardiogenic pulmonary edema, we recommend a trial of NPPV (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cardiogenic pulmonary edema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with hypoxemic respiratory failure due to causes other than cardiogenic pulmonary edema, we suggest a trial of NPPV (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hypoxemic respiratory failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an asthma exacerbation who continue to have severe symptoms despite initial bronchodilator therapy, we suggest a trial of NPPV (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NPPV may be beneficial in preventing recurrent respiratory failure following extubation if employed early. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=see_link&amp;anchor=H8#H8\">",
"       \"Extubation management\", section on 'Post-extubation management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once a patient has been selected to receive a trial of NPPV, it should be initiated as soon as possible. Patients who fail to improve or stabilize within one-half to two hours should be promptly intubated. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Initiation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    NPPV is generally safe. Most complications are local and related to the tightly fitting mask. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Potential harms'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/1\">",
"      Maheshwari V, Paioli D, Rothaar R, Hill NS. Utilization of noninvasive ventilation in acute care hospitals: a regional survey. Chest 2006; 129:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/2\">",
"      Demoule A, Girou E, Richard JC, et al. Increased use of noninvasive ventilation in French intensive care units. Intensive Care Med 2006; 32:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/3\">",
"      Celikel T, Sungur M, Ceyhan B, Karakurt S. Comparison of noninvasive positive pressure ventilation with standard medical therapy in hypercapnic acute respiratory failure. Chest 1998; 114:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/4\">",
"      Sweet DD, Naismith A, Keenan SP, et al. Missed opportunities for noninvasive positive pressure ventilation: a utilization review. J Crit Care 2008; 23:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/5\">",
"      Organized jointly by the American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Soci&eacute;t&eacute; de R&eacute;animation de Langue Fran&ccedil;aise, and approved by ATS Board of Directors, December 2000. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute Respiratory failure. Am J Respir Crit Care Med 2001; 163:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/6\">",
"      D&iacute;az GG, Alcaraz AC, Talavera JC, et al. Noninvasive positive-pressure ventilation to treat hypercapnic coma secondary to respiratory failure. Chest 2005; 127:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/7\">",
"      Scala R, Naldi M, Archinucci I, et al. Noninvasive positive pressure ventilation in patients with acute exacerbations of COPD and varying levels of consciousness. Chest 2005; 128:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/8\">",
"      Squadrone E, Frigerio P, Fogliati C, et al. Noninvasive vs invasive ventilation in COPD patients with severe acute respiratory failure deemed to require ventilatory assistance. Intensive Care Med 2004; 30:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/9\">",
"      Paus-Jenssen ES, Reid JK, Cockcroft DW, et al. The use of noninvasive ventilation in acute respiratory failure at a tertiary care center. Chest 2004; 126:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/10\">",
"      Nava S, Navalesi P, Conti G. Time of non-invasive ventilation. Intensive Care Med 2006; 32:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/11\">",
"      Collaborative Research Group of Noninvasive Mechanical Ventilation for Chronic Obstructive Pulmonary Disease. Early use of non-invasive positive pressure ventilation for acute exacerbations of chronic obstructive pulmonary disease: a multicentre randomized controlled trial. Chin Med J (Engl) 2005; 118:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/12\">",
"      Liesching T, Kwok H, Hill NS. Acute applications of noninvasive positive pressure ventilation. Chest 2003; 124:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/13\">",
"      Kacmarek, RM. Characteristics of pressure-targeted ventilators used for noninvasive positive pressure ventilation. Respir Care 1997; 42:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/14\">",
"      Ferguson GT, Gilmartin M. CO2 rebreathing during BiPAP ventilatory assistance. Am J Respir Crit Care Med 1995; 151:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/15\">",
"      Navalesi P, Fanfulla F, Frigerio P, et al. Physiologic evaluation of noninvasive mechanical ventilation delivered with three types of masks in patients with chronic hypercapnic respiratory failure. Crit Care Med 2000; 28:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/16\">",
"      Erickson SE, Shlipak MG, Martin GS, et al. Racial and ethnic disparities in mortality from acute lung injury. Crit Care Med 2009; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/17\">",
"      Soo Hoo GW, Santiago S, Williams AJ. Nasal mechanical ventilation for hypercapnic respiratory failure in chronic obstructive pulmonary disease: determinants of success and failure. Crit Care Med 1994; 22:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/18\">",
"      Hess, D. Noninvasive positive pressure ventilation: Predictors of success and failure for adult acute care applications. Respir Care 1997; 42:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/19\">",
"      Turner, RE. NIPPV: Face versus Interface. Respir Care 1997; 42:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/20\">",
"      Antonelli M, Conti G, Pelosi P, et al. New treatment of acute hypoxemic respiratory failure: noninvasive pressure support ventilation delivered by helmet--a pilot controlled trial. Crit Care Med 2002; 30:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/21\">",
"      Gregoretti C, Confalonieri M, Navalesi P, et al. Evaluation of patient skin breakdown and comfort with a new face mask for non-invasive ventilation: a multi-center study. Intensive Care Med 2002; 28:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/22\">",
"      Antonelli M, Pennisi MA, Pelosi P, et al. Noninvasive positive pressure ventilation using a helmet in patients with acute exacerbation of chronic obstructive pulmonary disease: a feasibility study. Anesthesiology 2004; 100:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/23\">",
"      Navalesi P, Costa R, Ceriana P, et al. Non-invasive ventilation in chronic obstructive pulmonary disease patients: helmet versus facial mask. Intensive Care Med 2007; 33:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/24\">",
"      Patroniti N, Foti G, Manfio A, et al. Head helmet versus face mask for non-invasive continuous positive airway pressure: a physiological study. Intensive Care Med 2003; 29:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/25\">",
"      Cavaliere F, Conti G, Costa R, et al. Noise exposure during noninvasive ventilation with a helmet, a nasal mask, and a facial mask. Intensive Care Med 2004; 30:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/26\">",
"      Racca F, Appendini L, Gregoretti C, et al. Helmet ventilation and carbon dioxide rebreathing: effects of adding a leak at the helmet ports. Intensive Care Med 2008; 34:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/27\">",
"      Holland AE, Denehy L, Buchan CA, Wilson JW. Efficacy of a heated passover humidifier during noninvasive ventilation: a bench study. Respir Care 2007; 52:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/28\">",
"      Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993; 341:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/29\">",
"      Brochard, L, Mancebo, J, Wysocki, M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/30\">",
"      Ferrer M, Esquinas A, Leon M, et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003; 168:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/31\">",
"      Wysocki M, Tric L, Wolff MA, et al. Noninvasive pressure support ventilation in patients with acute respiratory failure. A randomized comparison with conventional therapy. Chest 1995; 107:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/32\">",
"      Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/33\">",
"      Martin TJ, Hovis JD, Costantino JP, et al. A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. Am J Respir Crit Care Med 2000; 161:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/34\">",
"      Gay PC, Hess DR, Hill NS. Noninvasive proportional assist ventilation for acute respiratory insufficiency. Comparison with pressure support ventilation. Am J Respir Crit Care Med 2001; 164:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/35\">",
"      Wysocki M, Richard JC, Meshaka P. Noninvasive proportional assist ventilation compared with noninvasive pressure support ventilation in hypercapnic acute respiratory failure. Crit Care Med 2002; 30:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/36\">",
"      Fern&aacute;ndez-Vivas M, Caturla-Such J, Gonz&aacute;lez de la Rosa J, et al. Noninvasive pressure support versus proportional assist ventilation in acute respiratory failure. Intensive Care Med 2003; 29:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/37\">",
"      Girault C, Richard JC, Chevron V, et al. Comparative physiologic effects of noninvasive assist-control and pressure support ventilation in acute hypercapnic respiratory failure. Chest 1997; 111:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/38\">",
"      Vitacca M, Rubini F, Foglio K, et al. Non-invasive modalities of positive pressure ventilation improve the outcome of acute exacerbations in COLD patients. Intensive Care Med 1993; 19:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/39\">",
"      Ant&oacute;n A, G&uuml;ell R, G&oacute;mez J, et al. Predicting the result of noninvasive ventilation in severe acute exacerbations of patients with chronic airflow limitation. Chest 2000; 117:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/40\">",
"      Appendini L, Patessio A, Zanaboni S, et al. Physiologic effects of positive end-expiratory pressure and mask pressure support during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/41\">",
"      Peter JV, Moran JL, Phillips-Hughes J, et al. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet 2006; 367:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/42\">",
"      Nouira S, Boukef R, Bouida W, et al. Non-invasive pressure support ventilation and CPAP in cardiogenic pulmonary edema: a multicenter randomized study in the emergency department. Intensive Care Med 2011; 37:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/43\">",
"      Kacmarek RM. NIPPV: patient-ventilator synchrony, the difference between success and failure? Intensive Care Med 1999; 25:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/44\">",
"      Vignaux L, Vargas F, Roeseler J, et al. Patient-ventilator asynchrony during non-invasive ventilation for acute respiratory failure: a multicenter study. Intensive Care Med 2009; 35:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/45\">",
"      Vitacca M. New things are not always Better: proportional assist ventilation vs. pressure support ventilation. Intensive Care Med 2003; 29:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/46\">",
"      Calderini E, Confalonieri M, Puccio PG, et al. Patient-ventilator asynchrony during noninvasive ventilation: the role of expiratory trigger. Intensive Care Med 1999; 25:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/47\">",
"      Poponick JM, Renston JP, Bennett RP, Emerman CL. Use of a ventilatory support system (BiPAP) for acute respiratory failure in the emergency department. Chest 1999; 116:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/48\">",
"      Karnik AM. Noninvasive positive pressure ventilation: testing the bridge. Chest 2000; 117:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/49\">",
"      Antonelli M, Conti G, Moro ML, et al. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. Intensive Care Med 2001; 27:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/50\">",
"      Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/51\">",
"      Wunderink, RG, Hill, NS. Continuous and periodic applications of noninvasive ventilation in respiratory failure. Respir Care 1997; 42:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/52\">",
"      Demoule A, Girou E, Richard JC, et al. Benefits and risks of success or failure of noninvasive ventilation. Intensive Care Med 2006; 32:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/53\">",
"      Gu&eacute;rin C, Girard R, Chemorin C, et al. Facial mask noninvasive mechanical ventilation reduces the incidence of nosocomial pneumonia. A prospective epidemiological survey from a single ICU. Intensive Care Med 1997; 23:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/54\">",
"      Hess DR. Noninvasive positive-pressure ventilation and ventilator-associated pneumonia. Respir Care 2005; 50:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/55\">",
"      Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med 1998; 339:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/56\">",
"      Girou E, Schortgen F, Delclaux C, et al. Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients. JAMA 2000; 284:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/57\">",
"      Peter JV, Moran JL, Phillips-Hughes J, Warn D. Noninvasive ventilation in acute respiratory failure--a meta-analysis update. Crit Care Med 2002; 30:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/58\">",
"      Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001; 163:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/59\">",
"      Ram FS, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; :CD004104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/60\">",
"      Keenan SP, Sinuff T, Cook DJ, Hill NS. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature. Ann Intern Med 2003; 138:861.",
"     </a>",
"    </li>",
"    <li>",
"     Williams JW, Cox CE, Hargett CW, et al. Noninvasive Positive-Pressure Ventilation (NPPV) for Acute Respiratory Failure. Duke Evidence-based Practice Center; Agency for Healthcare Research and Quality (US), Rockville, MD 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/62\">",
"      Keenan SP, Powers CE, McCormack DG. Noninvasive positive-pressure ventilation in patients with milder chronic obstructive pulmonary disease exacerbations: a randomized controlled trial. Respir Care 2005; 50:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/63\">",
"      Conti G, Antonelli M, Navalesi P, et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med 2002; 28:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/64\">",
"      Diaz O, Iglesia R, Ferrer M, et al. Effects of noninvasive ventilation on pulmonary gas exchange and hemodynamics during acute hypercapnic exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/65\">",
"      Masip J, Roque M, S&aacute;nchez B, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA 2005; 294:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/66\">",
"      Winck JC, Azevedo LF, Costa-Pereira A, et al. Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema--a systematic review and meta-analysis. Crit Care 2006; 10:R69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/67\">",
"      Collins SP, Mielniczuk LM, Whittingham HA, et al. The use of noninvasive ventilation in emergency department patients with acute cardiogenic pulmonary edema: a systematic review. Ann Emerg Med 2006; 48:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/68\">",
"      Gray A, Goodacre S, Newby DE, et al. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 2008; 359:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/69\">",
"      Vital FM, Saconato H, Ladeira MT, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev 2008; :CD005351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/70\">",
"      Weng CL, Zhao YT, Liu QH, et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med 2010; 152:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/71\">",
"      Masip J, Betbes&eacute; AJ, P&aacute;ez J, et al. Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary oedema: a randomised trial. Lancet 2000; 356:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/72\">",
"      Nava S, Carbone G, DiBattista N, et al. Noninvasive ventilation in cardiogenic pulmonary edema: a multicenter randomized trial. Am J Respir Crit Care Med 2003; 168:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/73\">",
"      Rusterholtz T, Kempf J, Berton C, et al. Noninvasive pressure support ventilation (NIPSV) with face mask in patients with acute cardiogenic pulmonary edema (ACPE). Intensive Care Med 1999; 25:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/74\">",
"      Delclaux C, L'Her E, Alberti C, et al. Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: A randomized controlled trial. JAMA 2000; 284:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/75\">",
"      Keenan SP, Sinuff T, Cook DJ, Hill NS. Does noninvasive positive pressure ventilation improve outcome in acute hypoxemic respiratory failure? A systematic review. Crit Care Med 2004; 32:2516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/76\">",
"      Hernandez G, Fernandez R, Lopez-Reina P, et al. Noninvasive ventilation reduces intubation in chest trauma-related hypoxemia: a randomized clinical trial. Chest 2010; 137:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/77\">",
"      Schettino G, Altobelli N, Kacmarek RM. Noninvasive positive-pressure ventilation in acute respiratory failure outside clinical trials: experience at the Massachusetts General Hospital. Crit Care Med 2008; 36:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/78\">",
"      Zhang Y, Fang C, Dong BR, et al. Oxygen therapy for pneumonia in adults. Cochrane Database Syst Rev 2012; 3:CD006607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/79\">",
"      Hilbert G, Gruson D, Vargas F, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med 2001; 344:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/80\">",
"      Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999; 160:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/81\">",
"      Cosentini R, Brambilla AM, Aliberti S, et al. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. Chest 2010; 138:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/82\">",
"      Soroksky A, Stav D, Shpirer I. A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack. Chest 2003; 123:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/83\">",
"      Shivaram U, Miro AM, Cash ME, et al. Cardiopulmonary responses to continuous positive airway pressure in acute asthma. J Crit Care 1993; 8:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/84\">",
"      Meduri GU, Cook TR, Turner RE, et al. Noninvasive positive pressure ventilation in status asthmaticus. Chest 1996; 110:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/85\">",
"      Patrick W, Webster K, Ludwig L, et al. Noninvasive positive-pressure ventilation in acute respiratory distress without prior chronic respiratory failure. Am J Respir Crit Care Med 1996; 153:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/86\">",
"      Fern&aacute;ndez MM, Villagr&aacute; A, Blanch L, Fern&aacute;ndez R. Non-invasive mechanical ventilation in status asthmaticus. Intensive Care Med 2001; 27:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/87\">",
"      Lim WJ, Akram RM, Carson KV. Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database Syst Rev 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/88\">",
"      Nowak R, Corbridge T, Brenner B. Noninvasive ventilation. J Allergy Clin Immunol 2009; 124:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/89\">",
"      Confalonieri M, Calderini E, Terraciano S, et al. Noninvasive ventilation for treating acute respiratory failure in AIDS patients with Pneumocystis carinii pneumonia. Intensive Care Med 2002; 28:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/90\">",
"      Antonelli M, Conti G, Bufi M, et al. Noninvasive ventilation for treatment of acute respiratory failure in patients undergoing solid organ transplantation: a randomized trial. JAMA 2000; 283:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/91\">",
"      Adda M, Coquet I, Darmon M, et al. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. Crit Care Med 2008; 36:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/92\">",
"      Razlaf P, Pabst D, Mohr M, et al. Non-invasive ventilation in immunosuppressed patients with pneumonia and extrapulmonary sepsis. Respir Med 2012; 106:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/93\">",
"      Baillard C, Fosse JP, Sebbane M, et al. Noninvasive ventilation improves preoxygenation before intubation of hypoxic patients. Am J Respir Crit Care Med 2006; 174:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/94\">",
"      Schettino G, Altobelli N, Kacmarek RM. Noninvasive positive pressure ventilation reverses acute respiratory failure in select \"do-not-intubate\" patients. Crit Care Med 2005; 33:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/95\">",
"      Chu CM, Chan VL, Wong IW, et al. Noninvasive ventilation in patients with acute hypercapnic exacerbation of chronic obstructive pulmonary disease who refused endotracheal intubation. Crit Care Med 2004; 32:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/96\">",
"      Meduri GU, Fox RC, Abou-Shala N, et al. Noninvasive mechanical ventilation via face mask in patients with acute respiratory failure who refused endotracheal intubation. Crit Care Med 1994; 22:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/97\">",
"      Levy M, Tanios MA, Nelson D, et al. Outcomes of patients with do-not-intubate orders treated with noninvasive ventilation. Crit Care Med 2004; 32:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/98\">",
"      Fernandez R, Baigorri F, Artigas A. Noninvasive ventilation in patients with \"do-not-intubate\" orders: medium-term efficacy depends critically on patient selection. Intensive Care Med 2007; 33:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/99\">",
"      Confalonieri M, Gazzaniga P, Gandola L, et al. Haemodynamic response during initiation of non-invasive positive pressure ventilation in COPD patients with acute ventilatory failure. Respir Med 1998; 92:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/100\">",
"      Hill, NS. Complications of noninvasive positive pressure ventilation. Respir Care 1997; 42:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/101\">",
"      Mehta S, Jay GD, Woolard RH, et al. Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema. Crit Care Med 1997; 25:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/102\">",
"      Sharon A, Shpirer I, Kaluski E, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000; 36:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/103\">",
"      Bersten AD. Noninvasive ventilation for cardiogenic pulmonary edema: froth and bubbles? Am J Respir Crit Care Med 2003; 168:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/51/1850/abstract/104\">",
"      Ho KM, Wong K. A comparison of continuous and bi-level positive airway pressure non-invasive ventilation in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Crit Care 2006; 10:R49.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1636 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-4F96C3A324-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1850=[""].join("\n");
var outline_f1_51_1850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      INITIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ventilator type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interface",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mode",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Asynchrony",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      WEANING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COPD exacerbation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypoxemic respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Post-extubation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Immunocompromised",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      POTENTIAL HARMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1636\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1636|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/17/9499\" title=\"table 1\">",
"      Indicator success NPPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/54/17259\" title=\"table 2\">",
"      Contraindications to NPPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/3/4156\" title=\"table 3\">",
"      Nasal vs oronasal masks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/8/1164\" title=\"table 4\">",
"      Initiation protocol NPPV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=related_link\">",
"      Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/18/38183?source=related_link\">",
"      Extubation management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/5/12375?source=related_link\">",
"      Noninvasive positive pressure therapy of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=related_link\">",
"      Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_51_1851="Risk factors macrosomia";
var content_f1_51_1851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for fetal macrosomia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiparity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged gestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male fetus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous delivery of an infant weighing more than 4000 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Race and ethnicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genetic syndromes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George T Mandy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1851=[""].join("\n");
var outline_f1_51_1851=null;
var title_f1_51_1852="Substances removed hemapheresis";
var content_f1_51_1852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F60280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F60280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathologic substances removed by therapeutic hemapheresis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pathologic substance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Immunoglobulins",
"       </td>",
"       <td>",
"        Hyperviscosity syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Waldenstrom's macroglobulinemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Autoantibodies",
"       </td>",
"       <td>",
"        Myasthenia gravis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-GBM antibody disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Factor VIII inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipoproteins",
"       </td>",
"       <td>",
"        Hypercholesterolemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytes",
"       </td>",
"       <td>",
"        Hyperleukemic leukostasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelets",
"       </td>",
"       <td>",
"        Severe thrombocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal red cells",
"       </td>",
"       <td>",
"        Sickle cell disease (pain crisis, acute chest syndrome, stroke)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Circulating immune complexes",
"       </td>",
"       <td>",
"        Immune complex glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Protein-bound substances and toxins",
"       </td>",
"       <td>",
"        Thyroid storm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amanita phalloides toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperparasitemia",
"       </td>",
"       <td>",
"        Malaria, babesiosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1852=[""].join("\n");
var outline_f1_51_1852=null;
var title_f1_51_1853="CASH algorithm";
var content_f1_51_1853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    CASH algorithm",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score range",
"       </td>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        <strong>",
"         Color",
"        </strong>",
"       </td>",
"       <td rowspan=\"6\">",
"        1-6",
"       </td>",
"       <td>",
"        Light brown",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dark brown",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brown",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blue",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Architectural disorder",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        0-2",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          None/mild",
"         </strong>",
"        </p>",
"        <p>",
"         Colors and dermoscopic structures are distributed in an organized or slightly disordered manner.",
"        </p>",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Moderate",
"         </strong>",
"        </p>",
"        <p>",
"         The dermoscopic structures lose their uniformity and are distributed in an irregular manner.",
"        </p>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Marked",
"         </strong>",
"        </p>",
"        <p>",
"         The arrangement of colors and dermoscopic structures is completely disorganized (chaotic).",
"        </p>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <p>",
"         <strong>",
"          Symmetry",
"         </strong>",
"        </p>",
"        <p>",
"         (taking into account shape and dermoscopic structures)",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        0-2",
"       </td>",
"       <td>",
"        Bi-axial symmetry",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mono-axial symmetry",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bi-axial asymmetry",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        <strong>",
"         Homogeneity/heterogeneity of dermoscopic structures",
"        </strong>",
"       </td>",
"       <td rowspan=\"7\">",
"        1-7",
"       </td>",
"       <td>",
"        Network",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dots/globules",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streaks/pseudopods",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blue-white veil",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regression structures",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blotches",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymorphous vessels",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Interpretation: The total score can range between 2 and 17 points. A total score of 8 or more is considered to be suggestive of melanoma.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Henning JS, Dusza SW, Wang SQ, et al. The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. J Am Acad Dermatol 2007; 56:45.",
"     <br>",
"      Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1853=[""].join("\n");
var outline_f1_51_1853=null;
var title_f1_51_1854="Skull growth and development";
var content_f1_51_1854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Skull growth",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 368px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The brain grows from less than adult size to adult size within the first two years of life.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1854=[""].join("\n");
var outline_f1_51_1854=null;
var title_f1_51_1855="Role of nicotinic muscarinic";
var content_f1_51_1855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58052&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasympathetic innervation of airways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 396px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ganglionic transmission is mediated via nicotinic receptors (N), while the M",
"    <sub>",
"     1",
"    </sub>",
"    receptors may play a facilitatory role. M",
"    <sub>",
"     2",
"    </sub>",
"    receptors at the postganglionic terminal may inhibit release of acetylcholine (Ach), which acts on M",
"    <sub>",
"     3",
"    </sub>",
"    receptors on airway smooth muscle to cause bronchoconstriction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Barnes, PJ, Life Sciences, 1993; 52:521.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_51_1855=[""].join("\n");
var outline_f1_51_1855=null;
